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 Epidemiological studies have established that diabetes is protective against incident 
prostate cancer (CaP). However, the existing literature on the association of diabetes with 
CaP aggressiveness at diagnosis and progression is inconsistent, and research in racially 
diverse cohorts is limited. The goal of this dissertation was to examine the relationship 
between diabetes and CaP in cohort of men with incident CaP from the North Carolina-
Louisiana Prostate Cancer Project (PCaP), a population-based cohort of White Americans 
(Whites) and Black Americans (Blacks). Follow-up data for North Carolina participants was 
available from the Health Care Access and Prostate Cancer Treatment in North Carolina 
(HCaP-NC) cohort for on average 5 years after CaP diagnosis.  
 Specific aim 1 sought to assess the association between diabetes and CaP 
aggressiveness at diagnosis in Black and White participants in PCaP. High aggressive CaP 
was defined as Gleason sum ≥8, or prostate specific antigen >20 ng/ml, or Gleason sum =7 
and clinical stage cT3-cT4. We found that diabetes was not associated with high aggressive 
CaP in the overall cohort (OR: 1.04; 95% CI: 0.79, 1.37), Whites (OR: 1.00; 95% CI: 0.65, 
1.57), or Blacks (OR: 1.07; 95% CI: 0.75, 1.53). 
 Specific aim 2 sought to implement a CaP progression algorithm and to assess the 
association between diabetes and CaP progression in Black and White participants in 
HCaP-NC. 20.9% of HCaP-NC participants experienced CaP progression. Progression was 
more prevalent in Blacks (25.0%) than Whites (17.6%). Diabetes was not associated with 
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CaP progression in the cohort as a whole (HR: 0.86, 95%CI: 0.54, 1.35), Whites (HR: 1.03, 
95%CI: 0.50, 2.13), or Blacks (HR: 0.77, 95% CI: 0.43, 1.39). 
 Although obesity was not part of our primary aims, given the close relationship 
between obesity and diabetes we also examined the association of obesity, independent of 
diabetes, with CaP aggressiveness and CaP progression. Obesity, independent of diabetes, 
was positively associated with high aggressive CaP in Whites only (OR: 1.98; 95% CI: 1.14, 
3.43). No association was observed in Blacks or the cohort as whole. Similarly, obesity, 
independent of diabetes, was associated with CaP progression (HR: 1.79, 95% CI: 1.08, 
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 Prostate cancer is the most common incident cancer among men in the United 
States. According to Surveillance Epidemiology and End Results (SEER), 14% of men will 
be diagnosed with prostate cancer during their lifetime.1 Black men are much more likely to 
be diagnosed with and die from prostate cancer than white men. The incidence rate, from 
2008-2012, in black men is 214.5 cases per 100,000 person years compared to only 130.4 
cases per 100,000 person years in white men.1 Between 2008-2012 the age-adjusted death 
rate in black men was more than double that in white men. Numerous studies have shown 
that diabetes is associated with a reduced risk of incident prostate cancer.2-20 However, the 
impact of diabetes on prostate cancer aggressiveness at diagnosis and progression is less 
clearly understood.   
 Diabetes has been linked with tumor aggressiveness in a few studies, using the 
Gleason score of incident tumors as a marker of aggressiveness21-24. A study among 
patients from Boston and Chicago found that both white and black men with diabetes had a 
higher grade (Gleason score 8-10)25 at diagnosis as compared to men without diabetes, but 
that black men were more likely to be diagnosed with a higher Gleason score as compared 
to white men independent of diabetes.21 By contrast another study among Veterans found 
diabetes was significantly associated with a higher biopsy Gleason score in white men but 
not black men.23  
 Beyond the impact of diabetes on prostate cancer incidence and aggressiveness at 
diagnosis, understanding the impact of diabetes on prostate cancer progression is also 
important. Current measures of prostate cancer progression often do not distinguish 
between recurrent (prostate cancer is detected after a period of non-detection) and 
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persistent (prostate cancer remains continually detectable even after definitive treatment) 
and were largely established in white men. Moreover, other available population-based data 
sources such as SEER and SEER-Medicare cannot establish measures of progression, as 
necessary post-treatment PSA measures are not available in these datasets. 
 The North Carolina-Louisiana Prostate Cancer Project (PCaP) is an ideal population-
based cohort for assessing the impact of diabetes on prostate cancer aggressiveness at 
diagnosis and progression in both White Americans (Whites) and Black men (Black). The 
PCaP cohort is comprised of incident prostate cancer cases from North Carolina and 
Louisiana, half Black and half White at each site, all diagnosed with adenocarcinoma of the 
prostate through state tumor registries between July 2004 and August 2009. Black men (n= 
1,130) were enrolled at the same rate as white men (n= 1,128) using a randomized 
recruitment method.26 In addition, a subsequent study, Health Care Access and Prostate 
Cancer Treatment in North Carolina (HCaP-NC), followed North Carolina PCaP subjects for 
an average of 5 years after diagnosis.27  
 A composite measure of prostate cancer aggressiveness at diagnosis has previously 
been developed for PCaP. Key components of the PCaP aggressiveness algorithm include 
Gleason grade, clinical stage, and prostate specific antigen (PSA) at diagnosis. In this 
project, an algorithm for prostate cancer progression will be implemented in HCaP-NC. 
Because HCaP-NC is a well-characterized diverse population-based cohort with detailed 
clinical data, this sample provides an ideal context within which to establish a measure of 





Specific Aim 1: To assess the association between self-reported diabetes and 
prostate cancer aggressiveness at diagnosis in Black and White participants in PCaP. 
Rationale: Although research suggests that there is an association between diabetes 
and prostate cancer aggressiveness at diagnosis21-24, the impact of race on this association 
is not clearly understood despite that fact that Blacks are more likely to be diagnosed with 
both diabetes and prostate cancer than their white counterparts. To date only two studies 
have examined race differences.21,23  
Specific Aim 2a: To implement a prostate cancer progression algorithm in the HCaP-
NC follow-up cohort. 
Rationale: This aim seeks to implement a prostate cancer progression algorithm in 
the HCaP-NC cohort. This algorithm will refine the characterization of prostate cancer 
progression including distinguishing participants that have persistent vs. recurrent prostate 
cancer progression across treatment modalities including radical prostatectomy and 
radiation. Key inputs of the algorithm will be PSA values, PSA trend over time, and 
treatment failure.  This progression algorithm will allow us to comprehensively classify the 
progression profile of both Black and White American prostate cancer participants in HCaP-
NC.  
Specific Aim 2b: To assess the association between self-reported diabetes and 
prostate cancer progression in Black and White participants in the HCaP-NC follow-
up cohort. 
Rationale: Although several studies have shown a protective association between 
diabetes and incident prostate cancer, the association between diabetes and progression is 
less clear. Some studies have suggested that there is no association between diabetes and 
prostate cancer recurrence23,28,29 while other studies have suggested that diabetes may be 
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associated with an elevated risk of progression as measured by metastases and 
biochemical recurrence.21,30-33 Moreover, similar to aggressiveness at diagnosis the potential 
differences in the effect of diabetes on prostate cancer outcomes by race is not well studied.  
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CHAPTER 2: BACKGROUND 
2.1 Descriptive Epidemiology of Prostate Cancer 
 Prostate cancer is the most common incident cancer among men in the United 
States.1 According to the Surveillance, Epidemiology, and End Results (SEER), 14% of men 
will be diagnosed with prostate cancer during their lifetime.1 In 2016, there will be an 
estimated 180,890 new cases of prostate cancer.1,34 This represents 21% of all incident 
cancer cases in men.34 
 Although the 5-year survival rate for prostate cancer is 98.9%, there will be estimated 
26,120 deaths attributable to prostate cancer in 2016.34 Survival in prostate cancer is stage 
dependent with the 5-year relative survival among men with localized prostate cancer at 
100% compared to only 28.2% among those with distant (metastasized cancer).1  
 Black men are more likely to be diagnosed with and die from prostate cancer than 
their white counterparts. The incidence rate from 2008-2012 in black men is 214.5 cases per 
100,000 person years compared to only 130.4 cases per 100,000 person-years in white 
men.1 During this time period, the age-adjusted death rate in black men (46.3 per 100,000 
person-years) was more than double that in white men (19.8 per 100,000 person-years).1 
2.2. Prostate Anatomy and Prostate Cancer 
Biology 
 The prostate is located in front of the rectum, 
below the bladder, and wraps around the urethra. 
(Figure 1).35-37 The main function of the prostate is 
to produce an alkaline fluid that assists in both the (Taken from: http://cancer.uc.edu 
/cancerinfo/TypesOfCancer/ProstateCa
ncer.aspx.) 
Figure 1. Anatomy of Prostate 
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motility and nourishment of sperm38 The prostate is generally the size of a walnut, but can 
be much larger in older men.36  
 The prostate is divided into four anatomic zones: the peripheral zone, the central 
zone, the transition zone, and the anterior fibromuscular stroma.38,39 The peripheral zone lies 
against the rectum, and makes up the majority of healthy prostate gland.39 The central zone 
surrounds the ejaculatory ducts. The transition zone is located in the center of the prostate 
and surrounds the urethra. The fibromuscular stroma consists primarily of muscle tissue, 
and is adjacent to the bladder.39 Prostate cancer is generally a slow-growing cancer, and the 
vast majority of are adenocarcinomas—cancers that arises from gland cells.36 Approximately 
75% of prostate cancers originate in the peripheral zone, while about 15% arise from the 
transition zone.38,39 Few prostate cancers arise from the central zone.39 
2.3 Risk Factors and Symptoms of Prostate Cancer 
 Age is the single largest risk factor for prostate cancer. Prostate cancer is very rare 
in men under 40 years of age.38,40 Approximately 60% of prostate cancer occurs in men 65 
and older, and the median age at diagnosis is 66.40,41 Other major risk factors include family 
history and race. Men with a father or brother who had prostate cancer have double the risk 
of prostate cancer. This risk is further increased if a first-degree relative was diagnosed with 
prostate cancer prior to 60 or if more than one relative was diagnosed.38,40 As previously 
discussed, prostate cancer is more likely to occur and cause death in Blacks than other 
races.38,40 
 Men with prostate cancer are most commonly asymptomatic.42 However, symptoms 
of prostate cancer, more common in men with advanced disease, can include difficulty 
initiating urination, interrupted urination, frequent urination, difficultly completely emptying 
bladder, pain during urination, blood in urine, persistent pain in back, hip, or pelvis, and 
painful ejaculation.42    
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2.4 Measures and Markers of Prostate Cancer Aggressiveness 
 This section discusses commonly used measures of prostate cancer aggressiveness 
at diagnosis including Prostate Specific Antigen (PSA), Gleason Score, the American Joint 
Committee (AJCC) Staging System, and defines frequently used composite measures of 
aggressiveness. 
2.4.1 Prostate Specific Antigen (PSA) 
 The prostate specific antigen (PSA) is a glycoprotein produced by the prostate, and 
is responsible for liquefying seminal fluid.43 The earliest descriptions of PSA described it as 
a marker for semen that could be used in forensic studies. In the early 1980s, studies from 
Roswell Park found that PSA could be detected in human serum and was elevated in 
patients with prostate cancer.43 Subsequent research showed that PSA could be effectively 
used to monitor prostate cancer progression in men with prostate cancer. In 1986, the Food 
and Drug Administration (FDA) approved the use of PSA to monitor prostate cancer 
progression in these men.44 It was not until 1994 that the FDA approved use of the PSA as a 
screening test in asymptomatic men.44  
 Thus, PSA tests have been used both as (1) a prostate screening test in men not 
diagnosed with prostate cancer and (2) as a marker to see if the prostate cancer was 
responding to treatment or recurred after treatment completion in men with prostate cancer. 
Traditionally, a PSA value of above 4.0 ng/mL was considered suspicious for prostate 
cancer and would warrant a prostate biopsy, but some studies have even suggested that the 
PSA threshold for biopsy be lowered to ≥ 2.5 ng/mL43 However in May 2012, the U.S. 
Preventative Task Force recommended against using the PSA as a screening test for 
prostate cancer based on current evidence.45 The Prostate Cancer Prevention Trial found 
that with the 4ng/mL cutoff, the PSA a test only had a sensitivity of 20.5%; the specificity 
was much higher at 93.6%.46 Similarly, a pooled analysis by the American Cancer Society 
found that the sensitivity of the PSA test at the same threshold was 21% and the specificity 
  
8 
was 91%.47 However, the sensitivity of the PSA for high grade prostate cancer (Gleason 
Score ≥ 8) was somewhat better at 51%.47 The positive predictive value for the PSA is only 
30%,47 indicating that only a third of men with an elevated PSA actually have prostate 
cancer. 
 Specificity of PSA is problematic for screening because PSA can be elevated for a 
number of reasons other than prostate cancer. Non-cancerous reasons for a rise in PSA 
include prostatitis (inflammation of prostate), urinary tract infection, and benign prostatic 
hyperplasia (enlargement of the prostate).44,48,49 Studies have further suggested that 
ejaculation can raise PSA levels for 24-48 hours following ejaculation.50,51 In addition, 
“normal” PSA values can vary by race. PSA thresholds were largely established by studies 
in white men. More recent research has indicated that the PSA cutoff point may need to be 
lower in both Asian and Black men.44,52 PSA values can also vary across assays. Different 
commercial assays of the same sample often produce discordant results.53 Despite recent 
attempts by the World Health Organization (WHO) organization to standardize PSA assays, 
differences between assays still remain.53 These differences can complicate comparisons of 
PSA across patients and over time. Furthermore, PSA-based screening can lead to over-
diagnosis of indolent prostate cancer.  Prostate cancer detected by PSA can be slow-
growing, and ultimately have no real clinical impact on diagnosed individuals.44 A study of 
unscreened men, who died from causes other than prostate cancer, found that over 40% of 
men aged 60 and older had prostate cancer on autopsy.54 This percentage rose to almost 
60% in men 80 and older.54 Unnecessary treatment of such indolent cancers by radiation or 
surgery can result in complications including urinary incontinence, erectile dysfunction, 




2.4.2 Gleason Score 
 Gleason score is a commonly used marker of prostate cancer aggressiveness. The 
Gleason grading system is based on histologic patterns of carcinoma cells in prostate 
tissue.55 Prostate cells are obtained via a biopsy, and are examined by a pathologist who will 
assign the Gleason grade. Gleason grades range from 1 to 5. Grade 1 cells closely 
resemble normal prostate cells—they are well-defined, have smooth edges, and are closely 
packed. 40,55 By contrast, grade 5 cells are poorly differentiated with cell borders that are 
“raggedly infiltrative”; these cells are clearly abnormal.40,55 Grades 2 through 4 fall in 
between these two extremes.40 In general, the tissue sample is assigned two separate 
grades. The primary grade is assigned to the predominant grade present in the tissue 
sample while the secondary grade is assigned to the second most prevalent grade in the 
tissue sample. These are summed to obtain the Gleason score, which ranges from 2-10. 55 
There are a few exceptions to this rule. First, if 95% of the tumor consists of a single grade 
than that grade is multiplied by two to obtain the Gleason score.40,55 Second, if there are 
three grades present in the tissue, the highest grade is always included in the Gleason 
score even if the larger area consists of the two lower grades.40 
 In general, higher Gleason scores are indicative of aggressiveness and suggest that 
cancer is likely to spread.40 A Gleason score of 6 or less is referred to as “well-differentiated” 
or “low-grade”, a score of 7 is referred to “moderately differentiated” or “intermediate-grade”, 
and a score of 8 or greater is referred to “poorly differentiated” or “high grade”.40 However, 
one additional factor to consider is that identical Gleason scores can obtained in different 
ways. For example, if the primary grade is 4 and the secondary grade is 3, the Gleason 
Score is 7 (4+3). However, a Gleason Score of 7 can also be obtained with a primary grade 
of 3 and a secondary grade of 4 (3+4). This is important because the former (4+3) can 
potentially be prognostically worse given the predominant cancerous tissue is less 
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differentiated.56 Research has suggested that a 4+3 Gleason score (vs. 3+4 score) is 
associated with increased prostate cancer mortality.56 
2.4.3 American Joint Committee on Cancer (AJCC) Tumor, Node, Metastases (TNM) 
Staging System 
 The American Joint Committee on Cancer TNM Staging System can be used to 
determine a clinical stage which is based on a physical exam including a digital rectal exam 
(DRE), lab tests, biopsy, and imaging exams.40 However, for men that undergo a radical 
prostatectomy a pathologic stage can also be determined. This is based on the surgical 
specimen and examination of any tissue that was removed during surgery, and is generally 
more accurate than the clinical stage.40 Both staging methods use the same categories 
(discussed below) however, the T1 category is not used in pathologic staging.40 
 The TNM staging system consists of three categories: (1) The T categories that 
describe the clinical stage of the prostate cancer, (2) the N categories that describe whether 
the prostate cancer has spread regionally to the lymph nodes, and (3) the M categories that 
describe the whether the prostate cancer has metastasized.40 The T, N, M stages are 
described in Table 1.27  
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Table 1. Description of TNM Clinical Stages  
TNM Clinical Stages 
Tumor (T)  
T1 Tumor nonpalpable on DRE; tumor not seen on transrectal ultrasound (TRUS) 
          T1a Incidental finding in transurethral resection of prostate (TURP) specimen, tumor 
≤ 5% of specimen 
          T1b Incidental finding in TURP specimen, tumor >5% of specimen 
          T1c Non-palpable, not visable by TRUS, identified via biopsy after elevated PSA 
screen 
T2  Tumor palpable on DRE or tumor visible on TRUS 
          T2a Palpable or visible by TRUS, one lobe 
          T2b Palpable or visible by TRUS, both lobes 
T3 Tumor extends beyond prostate, possibly to seminal vesicles 
          T3a Extracapsular extension;  has not spread to seminal vesicles 
          T3b Seminal vesicle involvement 
T4 Cancer has spread to bladder neck, external sphincter, rectal, levator muscles, 
or pelvic side wall  
Node (N)  
NX Lymph nodes not assessed 
N0 No regional lymph node involvement 
N1 Metastases, regional lymph node(s) 
Metastasis (M)  
MX Distant metastases not assessed 
M0 No distant metastases 
M1a Non-regional lymph node involvement 
M1b Bone involvement 
M1c Other sites involved 
Taken from the PCaP Medical Abstraction Protocol
27
  
2.4.4 Composite Measures of Aggressiveness: Stage Grouping  
 After the TNM stage is assigned, a further categorization is possible. The stage 
group takes into account the TNM stage along with Gleason score and PSA.40 The stage 
group ranges from I to IV, where stage group I is the least advanced and stage group IV is 
the most advanced.40 If Gleason score and PSA values are not available, the stage group 
classification can be based on the TNM stage alone.40 The stage group along with the 
patient’s age and health status is used clinically to help plan treatment and predict 
prognosis.40 The stage groups are described in Table 2.  
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Table 2. Description of Prostate Cancer Stage Group 
Stage Group 
Stage I T1, N0, M0, Gleason score ≤ 6, and PSA less than 10 
 OR 
T2a, N0, M0, Gleason score ≤ 6, and PSA less than 10 
Stage II A        T1, N0, M0, Gleason score = 7, and PSA less than 20 
OR 
      T1, N0, M0, Gleason score ≤ 6, and PSA ≥ 10 and <20 
OR 
      T2a or T2b, N0, MO, Gleason score ≤ 7, PSA <20 
Stage IIB       T2c, N0, M0, any Gleason score, and any PSA 
OR 
       T1 or T2, N0, M0, and Gleason score, PSA ≥ 20 
OR 
       T1 or T2, N0, M0, Gleason score ≥ 8, and any PSA 
Stage III        T3, N0, M0, any Gleason score, and any PSA 
Stage IV        T4, N0, M0, any PSA 
OR 
        Any T, N1, M0, any Gleason score, and any PSA 
OR 
        Any T, any N, M1, any Gleason score, and any PSA 
Stage group definitions taken from American Cancer Society, Prostate Cancer Detailed Guide
40  
 The advent of regular PSA screening (mid 1990s – early 2010s) has also had an 
impact on the stage at diagnosis in prostate cancer patients. PSA screening allows prostate 
cancers to be detected at an earlier stage, and allows detection of disease that would not 
have been detected by DRE alone.57 This in turn has led to more prostate cancers being 
diagnosed at lower stages, and concurrently less prostate cancers being diagnosed at the 
higher stages (i.e. stage migration).57 According to SEER from 1975-1987 to 1988-1997, the 
percent of white prostate cancer patients with late stage disease fell from 18.1% to 7.5%.57 
During the same time period, Black patients experienced a similar decrease in late stage 
disease from 27.2% to 12.4%.57 
 Interestingly, screening and earlier detection have not led to a corresponding 
decrease in Gleason scores over time. The majority of newly diagnosed tumors after PSA 
testing adoption were Gleason Grade 5 to 7.58 One possible explanation for this is “grade 
inflation” over time. In a study by Albertson et al., pathologists assigned Gleason scores to 
tumors samples that were originally assigned a grade between 1990-1992. Blinded to the 
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original scores, the Gleason scores assigned by pathologists during re-examination from 
2002-2004 were significantly higher, and the mean score increased from 5.95 to 6.8.58 An 
editorial in the Journal of the National Cancer Institute, offers a few possible explanations. 
First, recently more Gleason scores are assigned using 3 Gleason grades. This method 
requires that the highest grade present be included even if it is a smaller portion of the 
tumor, and this in turn pushes the Gleason score upward.59 Second, since current clinical 
guidelines suggest that low-grade tumors do not necessarily warrant treatment, there could 
be an inclination to assign higher grades so that tumors do not go untreated.59  
2.4.5 Other Composite Measure of Aggressiveness: D’Amico and PCaP 
Classifications 
 In addition, to the stage grouping described above different measures of 
classification are often employed in prostate cancer research. The most frequently used 
research classification is the D’Amico classification. D’Amico and colleagues developed this 
classification system in 1998. This classification system was designed to group patients into 
low, intermediate, and high risk of biochemical recurrence following treatment with radical 
prostatectomy or radiation.60 Risk groups are defined using Gleason score, pre-treatment 
PSA, and clinical TNM stage.60 Under the D’Amico classification low risk is defined as 
clinical stage T1c or T2, PSA ≤ 10ng/ml, and Gleason score ≤ 6.61 Intermediate risk is 
defined as clinical stage T2b, Gleason score of 7, or PSA >10 to ≤ 20 ng/ml.61 High risk is 
defined as clinical stage T2c, PSA level >20 ng/mL, or Gleason score ≥ 8.61  
 In PCaP, an alternate measure of aggressiveness at diagnosis has previously been 
developed. Similar to the D’Amico classification key inputs for the PCaP measure of 
aggressiveness at diagnosis includes clinical stage, PSA, and Gleason score. This measure 
will be discussed in detail later.   
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2.5. Possible Markers of Prostate Cancer Progression (Persistent or Recurrent) 
 This section discusses commonly used measures of prostate cancer progression 
including biochemical recurrence, positive surgical margins, seminal vesicle invasion, and 
the initiation of secondary treatment. Although PSA was previously discussed as a 
screening tool it will now be discussed as a marker of progression (i.e. biochemical 
recurrence). 
2.5.1 Biochemical Recurrence  
 According to the NCI, biochemical recurrence (BCR) is an increase in PSA after 
definitive treatment with surgery of radiation.62 A 2007 paper, identified 166 different 
definitions of biochemical recurrence in the literature.63 Definitions are diverse and include 
variations such as two measures of 0.4 ng/mL and rising, PSA >0.2 ng/ml, PSA >0.4 ng/mL, 
3 consecutive rises in PSA after nadir (the lowest PSA value observed) has been reached, 
two consecutive PSA values >0.2 ng/mL.63,64 This variation in definition is further 
complicated by treatment type. After radical prostatectomy any PSA can be indicative of 
biochemical recurrence as the source of PSA production has been removed.65 Thus nadir is 
a PSA equal to 0. However, after treatment with radiation, PSA production is still possible. 
This makes it difficult to definitively define an absolute nadir PSA.65 According to the 2013 
American Urological Association best practice statement, among patients that had a radical 
prostatectomy, biochemical recurrence is defined as “an initial PSA value =0.2 ng/mL 
followed by a subsequent confirmatory PSA value =0.2 ng/mL”.66 Among radiation patients, 
the current consensus definition is the “phoenix definition”. Per this definition, biochemical 
recurrence is defined as a PSA of 2 ng/mL above nadir.67 
 Practically these variations in definition can have many clinical implications. For 
example, among patients treated with radiation, BCR defined as a PSA >0.2 ng/mL has a 
sensitivity of 91%, but a specificity of only 9%.65 The 5-year BCR free survival using this 
definition is 15%.65 By contrast using an alternate definition of BCR among radiation 
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patients, an increase of 2 ng/mL above nadir, the sensitivity is 74% and the specificity is 
much high at 82%.65 The 5-year BCR free survival is also much higher at 68%.65 In patients 
treated by radical prostatectomy a BCR defined as a PSA of 0.4 ng/mL and rising best 
predicted distant metastases.63 These variations can complicate comparing recurrence rates 
across studies and populations. 
2.5.2 PSA Doubling Time 
 PSA doubling time (PSADT) is most often calculated by taking the slope obtained 
from the linear regression of the log-transformed PSA by time and dividing by ln(2).68 This 
calculation assumes first-order kinetics and that PSA is rising in an exponential manner.68 A 
PSA working group that met at the National Cancer Institute (NCI) in 2006 recommends the 
following when calculating PSADT: (1) All PSA values should be ≥ 0.20 ng/ml, (2) all PSA 
values within the past 12 months should be included in the calculation, (3) only values from 
the past 12 months should be used, (4) a minimum of 3 PSA values is needed, and (5) PSA 
values should be obtained over a minimum of 3 months, with at least 4 weeks between PSA 
measures.68 There is however variation in how PSADT is calculated across studies. Some 
studies calculate PSA using only two PSA measures and use values over a two-year period 
following biochemical recurrence.23,30 Moreover PSADT can be impacted by a number 
factors including treatment type, type of PSA assay used, number of PSA measures used, 
and the length of time over which the PSA measures were taken.68 
 A shorter PSADT has been consistently associated with worse clinical outcomes. 
Men with a PSADT of less than 3 months have a high risk of death while men with a PSADT 
of greater than 15 months have a very low risk of death.68 In general, a longer PSADT is 
associated with both a lower risk as well as a longer time to metastases, prostate-cancer 
specific mortality, and all-cause mortality.68 Research shows this is analogous to a dose-
response relationship, with decreases in PSADT associated with increasing times to 
metastases and death.68 
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2.5.3 Positive Surgical Margins (a Predictor of Progression) 
 The presence of positive surgical margins can be assessed in men that have 
undergone radical prostatectomy. A positive surgical margin is defined as, “tumor extending 
to the inked surface of the prostatectomy specimen”.69 Positive surgical margins are found in 
11-38% of radical prostatectomy patients.69 Research has suggested they may be 
associated with many adverse clinical outcomes including BCR, local disease recurrence, 
and the use of secondary prostate cancer treatment.69 
2.5.4 Seminal Vesicle Invasion (a Predictor of Progression)  
 Seminal vesicle invasion is defined as “prostate cancer penetrating the muscular wall 
of the seminal vesicle.”70 The seminal vesicles are a pair of glands, located behind the 
prostate, that are responsible for producing the fluid component of semen. Seminal vesicle 
invasion is associated with biochemical recurrence.70 Prior research suggests the 5-year 
BCR-free survival in men with seminal vesicle invasion range anywhere from 5-60%.70 
2.5.5 Secondary Treatment 
 The presence of secondary treatment (treatment after initial curative therapy) can 
also be indicative of prostate cancer progression or recurrence. This generally refers to 
additional treatment after radical prostatectomy or completion of radiation therapy. 
Secondary treatments can include hormone therapy (androgen deprivation therapy), anti-
androgens, or chemotherapy.40  
 Androgen deprivation therapy (ADT), as the name implies, is designed to lower 
androgen levels. The primary androgens, testosterone and dihydrotestosterone can 
stimulate prostate cancer growth.40 There are several different treatment methods to lower 
androgen in men. The most extreme is orchiectomy or removal the testicles. The testicles 
are the primary source of androgen production, and removal can slow or eliminate prostate 
cancer growth.40 Less extreme androgen deprivation therapies include luteinizing hormone 
releasing (LHRH) hormone analogs and antagonists. Both reduce androgen levels, but 
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analogs cause a temporary flare in testosterone levels after initiation. This can be 
problematic in men with bone metastases.40 LHRH antagonists work similarly and do not 
cause this temporary flare.40 A third possibility are anti-androgens. Anti-androgens work by 
binding to the androgen receptor, and blocking androgens from binding. This treatment 
method is generally not used alone, but in conjunction with LHRH analogs and 
antagonists.40 A limitation of all androgen therapy is that in most men prostate cancer cells 
eventually develop androgen independent pathways. According to Schroeder et al. virtually 
all prostate cancers will become androgen independent over time.71 It is estimated that 
every year 25,000 men will develop androgen-independent prostate cancer (AIPC).72 
 Chemotherapy is not generally used for localized prostate cancer treatment. 
However, chemotherapy can be used if the prostate cancer has metastasized.40 The 
chemotherapy drug most commonly used in prostate cancer patients is docetaxel.40 In the 
most advanced prostate cancer cases, where there are metastases to the bones, drugs 
such as bisphosphonates or Denosumab are used. These drugs work by blocking 
osteoclasts. Osteoclasts are found in healthy bone cells, but can become overactive when 
there is bone metastases.40 These drugs reduce pain, help prevent bone fractures, and may 
slow progression of metastases. To the extent that the primary treatment for prostate cancer 
is commonly surgery or radiation, the initiation of these secondary treatments can be used 
as a marker of prostate cancer progression.  
2.5.6 Limitations of Current Measures of Prostate Cancer Progression 
 There are several limitations to the current methods of measuring progression. First, 
there is no standard definition of “progression”. There are hundreds of definitions of 
biochemical recurrence, with different PSA cut points. Some require only one PSA measure 
while others require a rising trend in PSA.63 Other possible measures of progression such as 
PSADT are not always calculated consistently. Second, these measure of progression do 
not distinguish between recurrent prostate cancer [prostate cancer that was successfully 
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treated (no PSA increase after nadir and no secondary treatment) and recurred] and 
prostate cancer that is persistent (prostate cancer that has never been successfully treated, 
i.e. treatment failure). Third, these measures of progression do not generally take into 
account long-term data.   
2.6 Diabetes and Prostate Cancer 
2.6.1 Diabetes and Incident Prostate Cancer 
 Several studies and meta-analyses have reported that diabetes reduces the risk of 
incident prostate cancer.2-20,73-79 This is in contrast to most other cancers where diabetes is 
associated with an increased risk. A few possible mechanisms for this inverse association 
have been hypothesized. First, insulin is a growth factor for prostate cancer cells.11 Thus 
men with diabetes, who have lower circulating insulin levels, may experience a slow or 
reduced growth of potential prostate cancer cells.11 Second, diabetes has been shown to be 
associated with benign prostatic hyperplasia (BPH). While BPH is not a risk factor for 
prostate cancer directly, it is possible that the chance of a biopsy detecting prostate cancer 
in an enlarged prostate is reduced.11 Finally, diabetics are likely to be taking other 
medications to manage their diabetes and other associated comorbidities. Medications such 
as statins (to lower cholesterol) and possibly metformin (to treat diabetes), commonly taken 
by diabetics, have also been associated with reduced prostate cancer risk.11,80-82  
2.6.2 Literature Review on the Impact of Diabetes in Men with Prostate Caner 
 Table 3 summarizes previous literature on diabetes and prostate cancer. This table 
includes studies that were conducted among men diagnosed with prostate cancer.  
However, five of the studies in the table were conducted in a cohort of men undergoing 
prostate biopsy, and therefore not definitively diagnosed with prostate cancer.83-87 This is 
clearly noted on the table, and these studies are excluded from the discussion that follows. 
Only studies with diabetes as the primary exposure were included, and studies looking at 
the impact of diabetes on incident prostate cancer were excluded. Studies were included 
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regardless of the prostate cancer outcome studied. The most common outcomes studied 
were mortality, Gleason score, and biochemical recurrence. PSA doubling time and 
metastases were less frequently studied. Since, a primary interest of this project is to 
examine race differences, any studies that directly examined race differences were denoted 
in the table.  
Summary of Findings 
 Non-prostate cancer mortality was significantly higher in diabetic prostate cancer 
patients as compared to non-diabetic prostate cancer patients.24,88-91 In addition, prostate 
cancer-specific mortality among diabetics vs. non-diabetics was also significantly higher in 
most studies.24,92,93 Hazard ratios, for prostate cancer-specific mortality, in these studies 
were consistent ranging from 1.23 to 1.32.24,92,93 By contrast, one study did report a non-
significant hazard ratio for prostate cancer-specific mortality in diabetics vs. non-diabetics 
(HR: 0.80, 95% CI 0.51, 1.25).90 This could be attributed to the fact that the study population 
in this study was recruited from a randomized clinical trial on treatment type.90 Randomized 
clinical trials are not always representative of the general population. In general, however, 
the literature showed that mortality (both non-prostate cancer and prostate cancer specific) 
was higher in diabetic prostate cancer patients vs. those without diabetes.  
 Four studies observed a significant positive association between diabetes and high 
grade disease at biopsy or baseline.21-24 In these studies high grade disease was either 
defined as a Gleason score ≥ 7 or a Gleason score of 8-10.21-24 In the three studies that 
reported hazard ratios there was consistency among the results with hazard ratios ranging 
from 1.59 (white men only) to 1.85  (overall).21,23,24 A study that looked at HbA1c levels, a 
marker of diabetes, noted a much stronger association (OR for diabetes among patients 
with HbA1c ≥ 7.8 vs. HbA1c <6.3: 6.60, 95% CI: 2.28, 19.08).29 However, a study in the 
same population using a clinical diagnosis of diabetes as the primary exposure was 
consistent with other results.23 One Chinese study noted no significant difference in mean 
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Gleason scores among diabetic and non-diabetic prostate cancer patients.94 However, this 
study had a relatively smaller sample size as compared to other studies, and only looked at 
unadjusted group level differences in mean Gleason score.94 
 Several studies examined the impact of diabetes on biochemical recurrence. Most 
studies report a non-significant association between diabetes and biochemical recurrence or 
BCR-free survival.23,28,29,32,95-97 However, some studies did report a significant, positive 
association in certain sub-groups. The Cancer or the Prostate Strategic Urologic Research 
(CaPSURE) study found that among men treated by radiation, history of diabetes was only 
associated with BCR in the low risk prognostic group (HR: 1.28, 95%CI: 1.28, 11.19).28 The 
low risk prognostic group was defined using the D’Amico classification.28 In addition, in men 
≤ 69 years of age treated with radiation, diabetes was associated with time to treatment 
failure (HR: 2.17, 95%CI: 1.02, 4.62).28 In Jayachandran et al., a study utilizing a Veterans 
Affairs medical database, there was a significant association observed between diabetes 
and BCR in white, obese men.28 One matched case-control study did note an overall 
significant positive association between diabetes and BCR (HR:1.55, 95%CI: 1.03, 2.33).31 
This could be attributed to the fact that this study was a matched case-control study where 
the authors matched diabetic cases with non-diabetic controls on their 5-year risk of BCR 
using the preoperative Kattan nomogram. In addition, this study had a fairly liberal definition 
of BCR as compared to other studies, requiring only one PSA value of 0.2 ng/mL.31  
 These results suggest that diabetes may be associated with BCR, but that this 
association may be limited to sub-groups such as those undergoing radiation, or those who 
are white and obese, or ≤ 69 of age.  A clear association between diabetes and BCR has 
not been established in the literature.  
 Only two studies examined diabetes and PSA doubling time. In Jayachandran et al. 
overall there was no significant difference between mean PSADT in men with and without 
diabetes (p=0.12).23 In Oh et al., a study based in a Korean medical center, diabetes was 
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associated with a PSADT of less than 9 months in men treated with radical prostatectomy, 
although the confidence interval was wide (OR: 2.687, 95% CI: 1.008, 7.164).30 
 In summary, the literature suggests that in men with prostate cancer diabetes is 
positively associated with non-prostate cancer mortality, prostate-specific mortality, and 
higher Gleason score. Most studies show that diabetes is not significantly associated with 
BCR, although certain sub-groups may be at increased risk. Few studies explore PSADT, 
and results are inconsistent.  
2.6.3 Studies Examining Diabetes and Race Differences 
 Three studies examined differences between Blacks and White men diagnosed with 
prostate cancer. In Mitin et al. a cohort of men with prostate cancer who were treated with 
radiation were studied.21 Study subjects (n=16,286) were men diagnosed with prostate 
cancer at the Chicago Prostate Cancer Center, community based medical centers in the 21st 
Century Oncology Practice, 3 academic institutions in Boston, or 2 community hospitals in 
Massachusetts.21 Diabetes status was self-reported and then verified by medical chart 
review by the treating radiation oncologist. Race was also based on self-report and 
categorized as black or non-black. Key outcomes included Gleason score 7 present (vs. 
Gleason score 7 absent) and Gleason score 8-10 present (vs. Gleason score 8-10 not 
present). Gleason score was measured at time of biopsy. Here the discussion will focus on 
Gleason score 8-10 present (vs. not present). Model covariates included black race, 
diabetes diagnosis, increasing age, PSA and DRE findings.  Results showed that diabetes 
was associated with a Gleason Score 8-10 in both black patients (OR:1.84, 95%CI: 1.08, 
3.13) and non-black patients (OR: 1.59, 95% CI: 1.33, 1.89).21 Moreover, among non-
diabetics, black race was associated with Gleason score 8-10 (OR: 1.36, (95% CI: 1.01, 
1.83).21 Among diabetic men, black race was associated with an elevated, but not 
statistically significant odds of Gleason score 8-10 (OR: 1.58, 95% CI: 0.98, 2.53).21 This 
study suggests that among men treated with radiation, diabetes is associated with a higher 
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Gleason score independent of race. In addition, black patients tend to have higher Gleason 
scores independent of diabetes, although the results were not statistically significant in 
diabetics.21 
 Unlike Mitin et al., which was limited to men treated with radiation, the study 
population in Jayachandran et al. consisted of men with prostate cancer who were treated 
by radical prostatectomy at Veteran Affairs Medical Centers  (n=1262).23 Data from medical 
centers in West L.A and Palo Alto, California, Augusta, Georgia, and Durham, North 
Carolina were compiled into the Shared Equal Access Regional Cancer Hospital (SEARCH) 
database. Diabetes status was determined from clinical notes, and based on physician 
diagnosis.  Self-determined race was defined as black or white, and several outcomes 
including BCR and PSADT were examined. The adjustment set included age, year of 
surgery, race, BMI, clinical stage, biopsy Gleason score (except in analysis of high grade 
disease), center, and preoperative PSA.23 All models included interaction terms for both race 
and obesity. Diabetes was associated with high grade disease in white (OR: 2.28, 95%CI: 
1.33, 3.91), but not black men (OR: 1.45, 95%CI: 0.90, 2.23). By contrast diabetes was 
associated with seminal vesicle invasion in black men (OR: 2.01, 95% CI: 1.02, 3.99), but 
not white men (OR: 1.44, 95% CI:0.64, 3.25).23 Diabetes was not associated with extra 
capsular extension or positive surgical margins in either black or white men.23 
 As previously mentioned, diabetes was significantly associated with time to BCR only 
in white, obese men (HR: 2.52, 95%CI: 1.40, 4.54).23 In all other sub-groups including non-
obese white and black (obese and non-obese) patients diabetes was not significantly 
associated with BCR.23 Similarly, in white, obese men, the mean PSADT was shorter in men 
with diabetes than those without diabetes, although this difference was not statistically 
significant (p=0.24). 23 Surprisingly, the PSA doubling time was significantly longer in black 
men with diabetes then black men without diabetes (p=0.02).23 
 The third study to examine race differences was Wu et al.33 This was a follow-up 
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study to Jayachandran et al., and also consisted men who had undergone radical 
prostatectomy in the SEARCH database (n=2058).33 The key outcome in this study was 
metastases. Metastases were most frequently diagnosed via bone scans requested by 
physicians. Additional imaging or a biopsy subsequently confirmed metastases. Models 
were either adjusted for pre-operative or post-operative features. Pre-operative features 
included age, PSA, BMI, biopsy tumor grade, clinical stage, radical prostatectomy year, and 
center. Post-operative features included age, PSA, BMI, race, radical prostatectomy tumor 
grade, margin status, extracapsular extension, seminal vesicle invasion, lymph node status, 
radical prostatectomy year, and center.33 Diabetes was not associated with metastases in 
black (HR:1.48, 95% CI: 0.43, 5.10) or white men (HR: 1.20, 95% CI: 0.51, 2.85) when 
adjusted for pre-operative features.33 Similarly, when adjusted for post-operative features, 
diabetes was not associated with metastases in black (HR: 1.31, 95%CI: 0.34, 5.09) or 
white men (HR: 1.47, 95%CI: 0.55, 3.93).33 However, obese men were at significantly 
increased risk for metastases independent of race.33  
 These studies do not show a consistent relationship between race, diabetes, and 
prostate cancer outcomes. In Mitin et al. diabetes was associated with a higher Gleason 
score in both black and non-black men, while in Jayachandran et al. diabetes was 
associated with a high Gleason score only in white men. These observed differences could 
possibly be attributed to differences in study populations. In Mitin et al. men were treated 
with radiation, while in Jayachandran et al. men were treated with radical prostatectomy.21 In 
addition, in Mitin et al. the non-black category included white, Asian, and Native American 
men.21 Jayachandran et al. showed that diabetes was associated with BCR only in white, 
obese men while Wu et al found that diabetes was associated with metastases only in 





The differences in treatment type and outcomes across these studies make it difficult 
to assess the impact of race, and the study proposed here will add valuable insight on the 
role of race and its impact on the relationship between diabetes and prostate cancer.  
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This column does not denote studies that addressed race by including race in the adjustment set. The studies had to present race-specific results for this column 
to be marked “yes”. 
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CHAPTER 3: METHODOLOGY 
3.1 Data Source: North Carolina-Louisiana Prostate Cancer Project (PCaP) 
3.1.1 Overview 
 The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a population-based 
cohort of patients with prostate cancer. All subjects were diagnosed with adenocarcinoma of 
the prostate between July 2004 and October 2007.27,101 Patients in both states were 
identified through state tumor registries. In North Carolina, the Rapid Case Ascertainment 
Core Facility, a collaboration between the University of North Carolina-Lineberger 
Comprehensive Cancer Center and North Carolina Central Cancer Registry identified 
patients.101 In Louisiana, the Louisiana Tumor Registry at the Louisiana State University 
Health Sciences Center identified patients.101 Eligibility criteria for PCaP subjects included: 
resident of North Carolina or Louisiana- study areas, first diagnosis of histologically 
confirmed adenocarcinoma of the prostate, 40-79 years old at diagnosis, can complete the 
study interview in English, does not live in an institution (i.e. nursing home), is not cognitively 
impaired or in a severely debilitated physical state, and is not under the influence of alcohol, 
severely medicated, or apparently psychotic at the time of the interview.101 Moreover, 
eligible men had to self-identify as at least part Black/Black or White American/White in 
response to the open-ended question, “What is you race?”.101  
 PCaP enrolled Blacks and Whites at an equal rate using a randomized recruitment 
method.26 Each case that was ascertained was assigned a randomized number.101 Cases 
were subsequently recruited into the study if their recruitment number was less than or 
equal for the race-specific sampling probability. The race-specific sampling probability for 
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Blacks was 100%, and 44% for Whites.101 There are 1,130 Blacks and 1,1128 Whites in the 
study.27 
3.1.2 Data Collection 
 Eligible patients were sent a letter explaining the PCaP study, and an enrollment 
specialist made a follow-up call one week later.101 Individuals that agreed to participate were 
visited in-home by a Registered Nurse.101 During the visit the nurse administered a 
questionnaire, took biologic samples, and made anthropometric measures.27 In addition, the 
nurse obtained informed consent for the release of tumor tissue and medical records during 
the in-home visit. The study questionnaire included questions on a wide variety of topics 
including background characteristics, occupation, family history, health status, prostate 
cancer diagnosis and screening history, medication use, Non-steroidal anti-inflammatory 
drugs (NSAIDs), and vitamins and supplements.101 Following the in-home visit, medical 
records were requested from the physicians (up to 3) of all consenting participants for 
standardized medical record abstraction.101 A relational database was used to abstract 
information from medical records regarding “comorbid conditions, family history of prostate 
cancer, urologic symptoms, indications for diagnostic examinations, physical examinations 
and laboratory assays at or near diagnosis, imaging used in staging, clinical stage and 
grade, and initial treatment information”.101 
3.1.3 HCaP-NC  
 HCaP-NC is the follow-up study of North Carolina PCaP participants.27 PCaP 
participants were followed, on average, 5 years after diagnosis. Data was collected annually 
from telephone interviews and medical record abstraction.27 The telephone interviews used 
standardized questionnaires. Follow-up medical records were available for 822 participants 




3.2 Methodology for Specific Aim 1  
 Specific Aim 1:  To assess the association between self-reported diabetes and 
prostate cancer aggressiveness at diagnosis in Black and White participants in PCaP. 
3.2.1 Study Population  
 The study population for Specific Aim 1 will be the entire PCaP cohort.  
3.2.2 Outcome 
 This aim utilized a previously developed measure of prostate cancer  
aggressiveness at diagnosis (Table 4).101 In PCaP 49% of the cohort (n=1102) has non-
aggressive tumors at diagnosis, 30% (n=675) had intermediate aggressive tumors, and 18%  
(n=396) had highly aggressive tumors.27  
Table 4. Prostate Cancer Aggressiveness at Diagnosis 
Outcome Definition 
Highly aggressive • Gleason sum  >=8 OR 
• PSA >20 ng/ml OR 
• Gleason sum=7 and stage cT3–cT4  
 
Non-aggressive  • Gleason sum<7 and stage cT1–cT2 and  
   PSA<10 ng/ml) 
 
 Intermediate aggressive All other cases 
 In our study, Gleason score alone (Gleason score ≥7) was used as a secondary 
outcome. 
3.2.3 Exposure 
 A self-reported measure of diabetes was used. The PCaP questionnaire asked the 
question, “Has a doctor or other health professional ever told you that you had diabetes of 
sugar diabetes?”. An inherent limitation of this measure is that it is self-reported. According 
to the Atherosclerosis Risk in Communities study (ARIC), the sensitivity of prevalent self-
reported diabetes ranges from 58.5% to 70.8% and the specificity ranges from 95.6% to 
96.8% depending on the reference definition employed.102 Another potential limitation of this 
exposure measure is that we do not know when patients were diagnosed with diabetes, e.g., 
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the duration of diabetes exposure or the severity of disease among diabetics. 27 It is 
important to note that we were interested in patients that already had diabetes prior to their 
prostate cancer diagnosis 
 Approximately 22% (n=475) of the PCaP cohort reported a diagnosis of diabetes. In 
PCaP, Africans Americans were more likely to have diabetes than their White counterparts. 
27% of Blacks (n=291) in PCaP had diabetes compared to 17% of Whites (n=184).  
3.2.4 Covariates  
3.2.4.1 Covariate Selection-Directed Acyclic Graph 
 Potential confounding covariates were assessed using a directed acyclic graph 
(DAG). Based on previous research and data available in PCaP, the following variables 
were included in our DAG: age, screening history, diabetes medication including insulin and 
metformin, socioeconomic status (SES), and smoking. The DAG can be seen in Figure 2. 
 
DAG was created using DAGitty (http://www.dagitty.net/).
103 
Figure 2. DAG for Specific Aim 1 
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 The minimally sufficient adjustment set identified by the DAG included: age, obesity, 
screening history, race, SES, and study site. The brief descriptions below highlight the 
associations illustrated in the DAG. 
 Age: The risk of diabetes increases with increasing age. Some research suggests 
older patients may be more likely to have slow-growing, less aggressive cancer. As 
previously discussed, one study found that up 60% of men 80 and older have undiagnosed 
prostate cancer on autopsy.54 Age is included in he adjustment set of all previous studies of 
diabetes and prostate cancer at diagnosis.  
 Obesity: Obesity is major risk factor for diabetes, and epidemiological evidence also 
suggests that obesity may be related to aggressive prostate cancer.104 A previous PCaP 
study found that obesity was significantly associated with aggressiveness at diagnosis.105 
 Screening history: PSA screening history is a strongly associated with prostate 
cancer aggressiveness at diagnosis. Men who undergo frequent PSA screening are more 
likely to be diagnosed with early-stage prostate cancer, as PSA screening detects prostate 
cancer that may not be detectable using other clinical methods such as DRE.   
 Race: Blacks are at increased risk for diabetes. Compared to Non-Hispanic white 
adults, Non-Hispanic black adults have a 77% higher risk of being diagnosed with 
diabetes.106 Moreover, black men are more likely to be diagnosed with and die from prostate 
cancer.41    
 SES: A lower socioeconomic status is associated with an increased risk of diabetes. 
107 Moreover, a lower SES may also be associated with higher aggressiveness at diagnosis. 
Men from a lower SES may be less likely to have a regular source of healthcare. This in turn 




 Study site: Patient characteristics, access to healthcare, and quality of health 
services may vary across North Carolina and Louisiana.  As such study site is included as a 
potential confounder in the DAG. 
 Variables not identified as potential confounders: It is hypothesized that insulin may 
increase the risk of prostate cancer risk while metformin may reduce prostate cancer risk, 
but the evidence is not conclusive.108,109 Although metformin and insulin were included on 
the DAG as potential risk factors for aggressiveness at diagnosis, this has not be clearly 
established in the literature. However, assuming they were risk factors for aggressiveness at 
diagnosis, they would not be potential confounders. As can be seen on the DAG, these 
variables would be on the causal pathway from diabetes to aggressiveness at diagnosis, 
and as such would not be adjusted for. Finally, although family history of prostrate cancer is 
associated with our outcome, it is not a potential risk factor for diabetes. As such it is not a 
potential confounder. 
3.2.4.2 Covariate Coding 
 Table 5 indicates how the covariates of interest were coded. Initial coding choices 
were based on prior PCaP research that assessed aggressiveness at diagnosis.110 
However, we reassessed the most appropriate coding choices by examining bivariate 
relationships between each covariate of interest and aggressiveness at diagnosis. 




Table 5. Variable Coding for DAG-identified Minimally Sufficient Adjustment Set 
Variable Coding  
Age continuous, 40-79 years of age 
 
BMI normal weight: 18.5 to <25.0 kg/m
2 
 
overweight: 25.0 to <30.0 kg/m
2 
 
obese: ≥ 30.0 kg/m
2 
 
PSA screening history  yes: participant had at least one PSA before prostate 
cancer diagnosis. 
 
no: participant did not have at least one PSA in the 12 







North Carolina, Louisiana 
 
SES  (Education) 
Less than high school 
High school graduate or some college 
College graduate or more 
3.2.5 Data Exploration  
 We began by a descriptive analysis of all the covariates. One-way frequencies were 
run for all categorical variables. For continuous variables, the distribution of each variable 
including the mean, median, range, and standard deviation were assessed. The amount of 
missing data was quantified, and the plausibility of any outliers was examined. Following 
univariate analyses, we conducted bivariate analyses with each covariate and 
aggressiveness at diagnosis. Aggressiveness at diagnosis was analyzed a 2-level variable 
(high-aggressive tumors vs. intermediate and non-aggressive tumors).   
3.2.6 Analytic Strategy 
3.2.6.1 Logistic Regression 
  Logistic regression was used to determine the relationship between diabetes and 
the dichotomous aggressiveness at diagnosis variable. Our primary models examined 
aggressiveness at diagnosis as a two-level outcome. It was analyzed as high-aggressive vs. 
intermediate and non-aggressive. This maximized power, and reflects the fact that patients 
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with high-aggressive tumors are clinically distinct. To begin we used an unadjusted, 
univariate logistic model with diabetes as the exposure and the dichotomous 
aggressiveness variable as the outcome. Multivariate analytic models were adjusted for the 
confounders identified by the DAG (Figure 2). Models were stratified by race to examine the 
role of race in the diabetes-aggressiveness association. Models were additionally stratified 
by treatment type. Most published studies are limited to single treatment types, and we 
stratified by treatment to determine if observed associations were restricted in some manner 
due the characteristics of participants within specific treatment groups 
 In a secondary analysis, we repeated all analyses with Gleason score alone as the 
outcome. Gleason score will be defined as a dichotomous outcome defined as Gleason 
score ≥7 vs. Gleason score <7.  The proposed unadjusted and adjusted analytic models are 
described next.  
 The unadjusted logistic model will be expressed as111:  
 Logit P (aggressiveness) = α + β1 (Diabetes) 
Where: 
             α  = logit P(aggressiveness) for non-diabetics     
    
 β1 =  log odds ratio for aggressiveness in diabetics vs. non-diabetics. 
    
The fully adjusted logistic model will be expressed as:   
 Logit P (aggressiveness) = α + β1 (Diabetes) + β2 (Race) +β3 (Age) + β4 (Overweight)    
           + β5 (Obesity)* + β6 (Screening History) + β7 (Less than high school education) + 
  β8 (College graduate or higher)  + β7 (Study Site)  
The models were run for the cohort as whole, among Blacks, and Whites. We additionally 
stratified models by treatment type. 
 Sensitivity Analysis*: Given the complicated relationship between obesity and 
diabetes, we ran models both adjusting and non-adjusting for obesity. If obesity is a true 
confounder (as shown in Figure 2) than it should be in the adjustment set. However, it is 
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possible that there is an alternative pathway whereby diabetes also increases the risk for 
obesity. This would put obesity on the causal pathway between diabetes and 
aggressiveness at diagnosis. In this pathway, obesity is a mediator and should not be 
adjusted for. Prior research on diabetes and aggressiveness at diagnosis is not consistent, 
with some studies adjust for obesity23,29 and other not adjusting for obesity.21,24 
3.2.6.2 Linear Regression 
 Prevalence differences were calculated to allow for direct comparisons across races. 
Linear regression with a binomial distribution was used to calculate the prevalence 
differences of high aggressive CaP in diabetic men vs. non-diabetic men. Models were 
adjusted for confounders identified from our DAG and include race, age, screening history, 
education, and study site. Models were also be stratified by race to examine race 
differences.  
The proposed unadjusted and adjusted analytic models are described next.  
The unadjusted logistic model will be expressed as:  
 Prevalence (aggressiveness) = α + β1 (Diabetes) 
Where: 
             α = Prevalence (aggressiveness) for non-diabetics     
    
 β1 = prevalence difference of aggressiveness in diabetics vs. non-diabetics.  
 
The fully adjusted logistic model will be expressed as:  
  Prevalence (aggressiveness) = α + β1 (Diabetes) + β2 (Race) +β3 (Age) +  
  β4 (Overweight)  + β5 (Obesity) + β6 (Screening History) + β7 (Less than high  
                       school education) + β8 (College graduate or higher)  + β7 (Study Site)  
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3.2.7 Power for Aim 1 (Primary Model) 
 Figure 3 shows the estimated power for our primary model, logistic regression using 
the composite measure of aggressiveness as our outcome. Since approximately 18% of our 
cohort had high aggressive tumors at diagnosis (n=396), to calculate power we used a 
case:control ratio of 4.6. Since approximately 22% of the cohort had diabetes we assumed 
an exposure prevalence of 0.22. Power calculations were based assuming a maximum case 
number of 396.  
 
Figure 3. Estimated Power for Aim 1 
We had greater than 80% power to detect odds ratios of 1.4 or higher. 
3.3 Methodology for Specific Aim 2a 
 Specific Aim 2a: To implement a prostate cancer progression algorithm in the 
HCaP-NC follow-up cohort. 
3.3.1 Study Population  




























 This aim was designed to create a prostate cancer progression outcome. Outcome 
definitions are outlined in Table 7 on the next page. The primary outcome was a binary 
outcome of progression (yes/no). However, the definition of “progression” was dependent on 
treatment type.  Within each treatment type, we further categorized patients into progression 
sub-types. Patients that undergo radical prostatectomy were categorized as having 
biochemical recurrence (BCR), persistent disease, other treatment failure, or successful 
treatment. Because patients that receive radical prostatectomy should have a post-
treatment nadir PSA that is undetectable, a true measure of persistence could only be 
measured in this treatment group.  
 Patients that undergo radiation were categorized as having biochemical recurrence, 
treatment failure, or successful treatment. Because patients that undergo radiation do not 
typically achieve a post-treatment nadir PSA of 0, persistence could not be defined in this 
group. Patients that chose watchful waiting, did not receive treatment of any type, or 




Table 7. Prostate Cancer Progression Outcome 



























 PSA ≥ 0.2 ng/ mL confirmed with a 
2
nd
 PSA of ≥ 0.2 ng/ mL after 
achieving nadir. [American 
Urological Association (AUA) 
definition]
66
. Nadir is defined as an 
undetectable PSA (PSA <0.1). 
 
 Patient does not achieve nadir after 
surgery. Nadir is defined as an 
undetectable PSA (PSA <0.1).  
 
 
 Received post radical prostatectomy 
treatment for prostate cancer 
(secondary treatment). This includes 
radiation, androgen deprivation 
therapy, or chemotherapy. Adjuvant 
radiation or adjuvant ADT will not be 
considered secondary treatment. 
(Radiation or ADT that is ≤ 6 months 
after radical prostatectomy is 
considered adjuvant). 
 





















 Nadir + 2 ng/ mL (Phoenix 
definition)
67
. Nadir will be defined as 
the lowest PSA achieved after 
initiation of radiation 
 
 Post radiation treatment for prostate 
cancer (secondary treatment). This 
includes radiation, androgen 
deprivation therapy or 
chemotherapy. Adjuvant ADT will not 
be considered secondary treatment. 
(ADT that is ≤ 1 year after start of 
radiation is considered adjuvant.  
 
 None of the above 
 
Watchful Waiting, no 
treatment recorded,  









Patients will be required to have at least one PSA measure within 6 months of radical prostatectomy      
  (RP). Patients with no PSA value within 6 months of RP will be excluded from analysis.  
b
 If a patient receives both External Beam Radiation and Brachytherapy, it will be considered as one  
  radiation treatment. 
c
 If ADT occurs prior to radical prostatectomy, radical prostatectomy will be considered the primary  
  treatment type. If ADT occurs less than one year before radiation, radiation will be considered the  
  primary treatment type. 
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 The first step in the creation of the progression outcome was manual assessment of 
progression in each HCaP-NC patient. For each patient, PSA measures and treatments 
received were graphed over calendar time. Using the definitions above each patient was 
manually assigned a progression outcome. The clinical team and other committee members 
reviewed the progression graphs of patients where the progression outcome was not clear 
based on the definitions in Table 7. The team came to consensus on the progression 
outcome of these patients, and this agreed upon progression outcome was used for all 
further analyses. 
3.4 Methodology for Specific Aim 2b  
 Specific Aim 2b: To assess the association between self-reported diabetes and 
prostate cancer progression in Black and White participants in the HCaP-NC follow-up 
cohort. 
3.4.1 Study Population  
 The study population for Specific Aim 2b was all HCaP-NC patients for which 
progression could be determined. 
3.4.2 Outcome 
 This utilized the progression outcome developed in Aim 2a. Our primary outcome 
was be time to progression across all treatment modalities (e.g. biochemical recurrence, 
persistence, or treatment failure). Note that the definition of progression will vary by 
treatment type as outlined in Table 7 above. Time to progression was determined as 
described below. 
 Radical prostatectomy: Follow-up began on date of surgery. Patients with 
biochemical recurrence were recorded as having a progression event at first PSA ≥ 0.2 
ng/mL after nadir given that there is a second confirmatory PSA ≥ 0.2 ng/mL (AUA 
definition). Persistent patients (those that never achieve nadir) were recorded as having a 
progression event 90 days after surgery. Patients that received secondary treatment were 
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recorded as having a progression event at date secondary treatment was initiated. For all 
other patients that were successfully treated, patients were censored at end of follow-up (i.e. 
date of last PSA measurement available).  
 Radiation: Follow-up began at date of radiation start. Patients were recorded as 
having a progression event at first PSA that is 2 ng/mL above nadir. Patients that received 
secondary treatment were recorded as having a progression event at date secondary 
treatment was initiated. For all other patients that were successfully treated, patients were 
censored at end of follow-up (i.e. date of last PSA measurement available). 
3.4.3 Exposure 
 The previously discussed self-reported measure of diabetes will be used. 
3.4.4 Covariates  
3.4.4.1 Covariate Selection-Directed Acyclic Graph 
 Potential confounding covariates were assessed using a directed acyclic graph 
(DAG). Because potential confounders conceptually have a similar relationship with 
progression as aggressiveness at diagnosis, the DAG was very similar to the one for 
Specific Aim 1. The main difference is, now, aggressiveness at diagnosis is included on the 
DAG as a potential confounder (Figure 4). However, as can be seen in the DAG, 
aggressiveness at diagnosis is on the causal pathway between diabetes and progression. 
As such we did adjust for it in our primary analysis. In addition, because all follow-up 
participants are form North Carolina, study site is not included in the DAG. 
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DAG was created using DAGitty (http://www.dagitty.net/).
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Figure 4. DAG for Specific Aim 2b 
 The minimally sufficient adjustment set identified by the DAG included: age, obesity, 
screening history, race, SES, study site, and aggressiveness at diagnosis. However, given 
that over 94% of the analytic cohort had a history of PSA screening, screening was not 
included in our final models.  
3.4.4.2 Covariate Coding 
 Covariate coding was similar to that described in Specific Aim 1. However, due to 
limited sample size BMI (obese/non-obese) and education (college degree/no college 
degree) were coded as binary variables. 
3.4.5 Data Exploration  
 Data exploration was similar to that described in specific Aim 1. We began by a 
descriptive analysis of all the covariates. Following univariate analyses, we conducted 




3.4.6 Analytic Strategy 
 Survival analysis was used to determine the relationship between diabetes and time 
to progression (yes/no) using the entire HCaP-NC cohort. Definitions of progression vaired 
by treatment type as outlined in Table 7.  To begin we compared time to progression in 
diabetic patients vs. non-diabetic patients using Kaplan Meir plots. Differences in survival 
between diabetics and non-diabetics were evaluated using the log-rank test.112 The log rank 
test tests the null hypothesis that Sdiabetics (t) = Snon-diabetics (t) for all t, where t =time and 
S=survival.112 We used an a-priori alpha = 0.05 to determine if survival probabilities are 
significantly different. The analysis was repeated, stratifying by race. 
 Next we calculated hazard ratios (HRs) for time to progression (yes/no) in diabetic 
patients vs. non-diabetic patients using Cox proportional hazards. For all analyses, we first 
assessed the proportional hazard assumption. The proportional hazard assumption for each 
categorical covariate was assessed by visually examining Kaplan-Meier and log-(log) plots. 
For continuous variables, the proportional hazard assumption was assessed using 
Schoenfeld Residuals. If the plots or Schoenfeld residuals indicated a potential violation of 
the proportional hazards assumption, we determined whether the interaction between time 
and that covariate was statistically significant (p-value ≥ 0.05) in an unadjusted model. Time 
was assessed using a liner, exponential, and cubic term. If the interaction was statistically 
significant, we retained an interaction term between that covariate and the appropriate 
measure of time (i.e. if the time trend is linear, we will use linear measure of time) in our final 
model. 
 Adjusted multivariable models will be adjusted for the confounders identified by the 
DAG (Figure 4). Models will be stratified by race to assess the role of race in the diabetes-
progression association. 
 Sensitivity Analysis*: Although we did not adjust for aggressiveness at diagnosis in 
our primary analysis as discussed (it is on the causal pathway) we will adjust for both our 
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composite measure of prostate cancer aggressiveness and Gleason score in a sensitivity 
analysis. This will be done to maintain consistency with prior literature. 
 The unadjusted Cox proportional hazard model will be expressed as the following 
(given non-diabetics are the reference and assumption of proportional hazards is met)112: 




 The null hypothesis is given by h(t) = h0(t)  
 h0(t) = hazard for progression of a non-diabetic individual at time t  
 exp [β1] = hazard ratio for time to progression in diabetics vs. non-diabetics 
 The multivariable Cox model will be expressed as the following (given non-diabetics 
are the reference and assumption of proportional hazards is met): 
  h(t) = h0(t) exp [ β1(Diabetes) + β2(Treatment type) + β3(Race) + β4(Age) +    
                     β5(Obesity) + β6(Screening History) + β7(College Education) +     
The proposed analyses for specific aim 2b are summarized in table 8. 
 













































 PSA screening history was identified as confounder by our DAG. However, it was not included in 





3.4.7 Power for Aim 2b 
 A two-sided log rank test was used to calculate power for Aim 2. Since 22% of the 
HCaP cohort had diabetes and, on average, we have 5-years of follow-up data, power was 
calculated assuming a 22% frequency of diabetes and 5-years of follow-up time. Previous 
research indicates that 20-30% of the prostate cancer patients will experience prostate 
cancer progression,23 and as such the estimated power in the graph below is calculated 
assuming that 25% of non-diabetics will have prostate cancer progression. Figure 5 shows 
the estimated power for Aim 2. 
 
Figure 5. Estimated Power for Aim 2b 



















Estimated Power for 25% Progression in Non-Diabetics 
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CHAPTER 4: THE ASSOCIATION OF DIABETES AND OBESITY WITH PROSTATE 
CANCER AGGRESSIVENESS AMONG BLACK AMERICANS AND WHITE AMERICANS 
IN A POPULATION-BASED COHORT 
4.1 Introduction 
 Prostate cancer (CaP) is the most common incident cancer among men in the United 
States. The Surveillance Epidemiology and End Results (SEER) reported that, 14% of men 
will be diagnosed with CaP during their lifetime.1 An estimated 220,800 new cases of CaP 
and 27,540 CaP deaths occurred in the United States during 2015.113 CaP is a disease of 
disparities. Black Americans (Blacks) are more likely to be diagnosed with and die from CaP 
than White Americans (Whites). The incidence of CaP from 2008-2012 is higher in Blacks at 
214.5 cases per 100,000 compared to 130.4 cases per 100,000 in Whites.1 The age-
adjusted death rate in Blacks was more than double that in Whites between 2008-2012.1  
 Numerous studies have shown that diabetes is associated with a reduced risk of 
incident CaP.73-79,114 Possible explanations for this inverse association include lower 
circulating levels of growth factors, such as insulin and testosterone, and decreased CaP 
detection among diabetic men.23,75,115  Diabetics are more likely to be obese than their non-
diabetic counterparts.116 Digital rectal exam (DRE) detection and prostate biopsy are more 
difficult in obese men, and obese men may have lower levels of prostate specific antigen 
(PSA), either of which could contribute to lower CaP detection rates.75,115,117,118  
 Studies among men diagnosed with CaP show that diabetes and obesity are 
positively associated with CaP aggressiveness.21,23,24,105,118-123 The positive association 
between diabetes and CaP aggressiveness is hypothesized to result from high aggressive 
prostate CaP surviving in a low-insulin, poor growth environment, an increased likelihood 
that CaP that does get detected is aggressive, and the changing glucose profile of diabetics 
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throughout the CaP course.23,115 Newly diagnosed diabetics, in particular, likely have high 
insulin levels that create an environment that promotes CaP growth.115 The positive 
association between diabetes and CaP aggressiveness observed in the literature is limited 
to studies with clinic or hospital-based populations or patients undergoing a single treatment 
type. Few studies have included sufficient numbers of Black men to examine the role of race 
on the diabetes-CaP aggressiveness association, and the two existing studies have yielded 
different results.21,23  
 We examined the association of diabetes and obesity, independent of diabetes, with 
high aggressive CaP at diagnosis, defined as a Gleason sum ≥8, or PSA >20 ng/ml, or 
Gleason sum =7 and clinical stage cT3-cT4. Our study population was a large, population-
based cohort of men who had incident CaP, were over-sampled for Blacks, were diagnosed 
in the PSA screening era, and participated in the North Carolina-Louisiana Prostate Cancer 
Project (PCaP). This analysis builds on previous PCaP research that found obesity was 
associated with CaP aggressiveness at diagnosis, by accounting for the diabetic status of 
PCaP research subjects.105   
4.2 Methods 
4.2.1 Study Population and Data Collection 
 PCaP has been described in detail.101 PCaP is a population-based cohort of 
research subjects with incident CaP. All research subjects were diagnosed with 
adenocarcinoma of the prostate between July 2004 and August 2009, and were identified 
using state tumor registries. Eligibility criteria for PCaP research subjects included: resident 
of North Carolina or Louisiana- study areas, first diagnosis of histologically confirmed 
adenocarcinoma of the prostate, 40-79 years old at diagnosis, could complete the study 
interview in English, did not live in an institution (i.e. nursing home), not cognitively impaired 
or in a severely debilitated physical state, and not under the influence of alcohol, severely 
medicated, or apparently psychotic at the time of the interview. Moreover, eligible men had 
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to self-identify as African American/Black or Caucasian/White in response to the open-
ended question, “What is your race?”. 
 PCaP enrolled Blacks and Whites at an equal rate using a randomized recruitment 
method.26 Participation rates were 62% in North Carolina, 73% in pre-hurricane Katrina 
Louisiana, and 63% in post-hurricane Katrina Louisiana. 1,130 Blacks and 1,128 Whites 
enrolled in PCaP. 
 We excluded 25 research subjects that were underweight [body mass index (BMI) < 
18.5] and 84 research subjects with missing information on the outcome (CaP 
aggressiveness) from our analytic group. Furthermore, 17 research subjects were excluded 
due to missing information on diabetes (4 research subjects responded they did not know 
their diabetes status and 13 research subjects did not have their diabetes status recorded). 
Additional research subjects were excluded due to missing covariate information (screening 
history, body mass index (BMI), or education) (n=83). Our final analytical sample included a 
total of 2049 research subjects (94% of PCaP research subjects with CaP aggressiveness 
defined at diagnosis) of which 1058 were White and 991 were Black. Although Black 
research subjects were more likely to be excluded than White research subjects, the overall 
distribution of CaP aggressiveness, diabetes, and covariates was similar for Blacks in the 
full PCaP cohort and Blacks in the analytic sample. However, excluded Black men were 
more likely to be from Louisiana (74.1% excluded men vs. 52.7% included men), less likely 
to have a college education (5.9% vs. 15.8%), less likely to be obese (28.0% vs. 39.8%), 
and less likely to receive either RP nor radiation (43.2 % vs. 64.8%) than those included in 
the analytic cohort. Similar to Black men, excluded White men were more likely to be 
Louisiana (68.6% vs. 52.4%), less likely to have a college education (14.3% vs. 43.6%), and 
less likely to receive either RP nor radiation (51.5% vs. 72.3%) than those included in the 
analytic cohort. Excluded white men were also more likely to be diabetic (27.7% vs. 16.7%) 
than included white men.  
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 The primary outcome was high aggressive CaP based on a composite of diagnostic 
PSA, clinical stage and Gleason sum. We also evaluated CaP aggressiveness solely based 
on Gleason sum. The sample consisted of 2207 research subjects (98% of the PCaP 
cohort) when the analysis was restricted to Gleason sum, 
 Research subjects who agreed to participate were visited by a Registered Nurse. 
The nurse administered a questionnaire, took biologic samples, and made anthropometric 
measures during an in-home visit. The nurse also obtained informed consent for the 
interview and specimen collection and release of tumor tissue and medical records. The 
study questionnaire included questions on comorbidities, such as diabetes, education level, 
and CaP screening history.  
 Medical records were requested from the physicians (up to 3) of all consenting 
research subjects for standardized medical record abstraction. Medical record abstraction 
included information regarding physical examinations and laboratory assays at or near 
diagnosis, clinical stage, Gleason sum, PSA measures, and initial CaP treatment. 
4.2.2 Outcome, Exposure, and Covariate Measurement 
 Our primary outcome of interest was a composite measure of CaP aggressiveness at 
diagnosis 101. High aggressive CaP was defined as Gleason sum ≥8, or PSA >20 ng/ml, or 
Gleason sum =7 and clinical stage cT3-cT4. Low aggressive CaP was defined as Gleason 
sum <7 and clinical stage cT1-cT2 and PSA <10 ng/ml. Other CaP was defined as 
intermediate aggressive. Low aggressive and intermediate aggressive CaP were collapsed 
into a single category in all our analytic models. We also analyzed CaP aggressiveness 
using Gleason sum alone to allow comparison with previous studies. Gleason sum was 
analyzed as a binary variable with high aggressiveness defined as Gleason sum ≥ 7. 
 Our primary exposures of interest are diabetes and obesity, independent of diabetes. 
PCaP research subjects self-reported diabetes status when asked the question, “Has a 
doctor or other health professional ever told you that you had diabetes or sugar diabetes?”. 
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Responses were recoded as “yes”, “no”, “refused”, or “don’t know”. Research subjects who 
did not know their diabetes status or refused to answer were excluded from our analysis 
(n=17, 0.8% of PCaP cohort). Obesity was determined using body mass index (BMI). BMI 
was calculated using standardized anthropometric measurements at the home visit, and 
research subjects were categorized as normal (BMI 18.5 to <25), overweight (BMI 25 to 
<30), or obese (BMI ≥ 30) using World Health Organization classifications. We removed BMI 
from our adjustment set in a sensitivity analysis, because obesity may be both a precursor 
and result of diabetes. In addition, in another sensitivity analysis we examined the 
association of diabetes with aggressiveness at diagnosis only among obese men. 
 Covariates were selected based on known confounders in the literature and to 
maintain consistency with prior PCaP studies and included race, age, screening history, 
education, and study site. Race was based on self-report, and all research subjects were 
categorized as either White or Black. Age was calculated based on age at diagnosis and 
coded as a continuous variable. Screening history was based on self-report and defined as 
having at least one PSA or Digital Rectal Exam (DRE) prior to CaP diagnosis. Education 
was based on self-report and categorized as less than high school, high school graduate or 
some college, or college graduate and above. Study site was categorized as North Carolina 
or Louisiana.  
 Research subjects were categorized as having undergone radical prostatectomy 
(RP) or radiation using medical records. Research subjects who had both RP and radiation 
were included in the RP group. The radiation group included research subjects who had 
either external beam radiation or brachytherapy. Research subjects who did not receive 
treatment, were on watchful waiting, or only received Androgen Deprivation Therapy (ADT) 
were included in analyses of the entire cohort, but were not included in treatment-stratified 




4.2.3 Statistical Analysis 
 Logistic regression was used to assess the association between diabetes and BMI 
with the composite binary outcome (aggressive CaP at diagnosis) in our primary analysis. 
Multivariable models were adjusted for race, age, screening history, education, and study 
site. Models were stratified by race to examine race differences. Models were stratified by 
treatment type to facilitate comparison with other single-treatment studies. We ran 
multivariable models without adjustment for BMI in a sensitivity analysis. 
 Logistic regression was used to assess the association between diabetes and BMI 
with Gleason sum alone using the same adjustment set as analyses with our composite 
outcome. Models were stratified by race.  
 Prevalence differences were calculated to allow for direct comparisons across races 
in a secondary analysis. Linear regression with a binomial distribution was used to calculate 
the prevalence differences of high aggressive CaP. Diabetes and BMI were our exposures 
of interest. Models were adjusted for race, age, screening history, education, and study site, 
and were also stratified by race to examine race differences.  
 All analyses were conducted using SAS 9.4 (Cary, NC). 
4.3 Results 
4.3.1 Characteristics of the PCaP Cohort (Table 9) 
 The mean age of research subjects at diagnosis was 63 years. The majority of 
research subjects had CaP screening using PSA or DRE prior to CaP diagnosis. Research 
subjects were enrolled in approximately equal numbers in North Carolina and Louisiana. 
Approximately half of the cohort was a high school graduate or had some college education. 
PCaP research subjects were more likely to be overweight or obese than normal weight.  
21.6% of the cohort had diabetes, and 17.9% of the cohort had high aggressive CaP using 
our composite measure of aggressiveness. 
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 Blacks (n=991) were slightly younger than Whites (n=1058). Whites were more likely 
than Blacks to have undergone CaP screening prior to diagnosis. There were approximately 
equal numbers of Whites and Blacks at each study site. Whites were more likely to be 
college graduates or above, while blacks were more likely to have less than a high school 
education. Blacks were more likely to have diabetes (26.8%) than Whites (16.7%), and were 
more likely to have high aggressive CaP at diagnosis (20.6% vs. 15.3%). 
 Sixty-eight percent of the PCaP cohort was treated with RP or radiation. Treated 
research subjects were more likely to have diabetes (24.9% vs. 20.1%), less likely to be 
from North Carolina (43.5% vs. 49.3%), more likely to have less than a high school 
education (24.8% vs. 17.1%), more likely to have high aggressive CaP (23.4% vs. 15.4%), 
and were older in age at diagnosis (66 years vs. 63 years). Whites were more likely to have 
received treatment than Blacks. 
4.3.2 Diabetes and Obesity (Table 10) 
 The OR for diabetes and high aggressive CaP was close to the null after adjustment 
for age, race, CaP screening history, study site, education, and BMI (OR: 1.04; 95% CI: 
0.79, 1.37). The association of diabetes and high aggressive CaP was similar in race-
specific adjusted models for Whites (OR: 1.00; 95% CI: 0.65, 1.57) or Blacks (OR: 1.07; 
95% CI: 0.75, 1.53). Obesity, adjusted for diabetes, was associated with an elevated odds of 
high aggressive CaP in the overall cohort (OR: 1.37; 95% CI: 0.99, 1.92) and Whites (OR: 
1.98; 95% CI: 1.14, 3.43), but not Blacks (OR: 1.09; 95% CI: 0.71, 1.67) in adjusted models.  
 Models not adjusted for BMI in a sensitivity analysis did not show an association 
between diabetes and high aggressive CaP  [Overall (OR: 1.10; 95% CI: 0.84, 1.45), Whites 
(OR: 1.14; 95% CI: 0.73, 1.76), or Blacks (OR: 1.09; 95% CI: 0.77. 1.55)]. In addition, 
models restricted to only obese men did not show an association between diabetes and high 
aggressive CaP [Overall (OR: 1.00; 95% CI: 0.68, 1.47), Whites (OR: 0.79; 95% CI: 0.43, 
1.43), or Blacks (OR: 1.19; 95% CI: 0.71. 2.00)]. 
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 We examined treatment specific ORs to facilitate comparison with existing literature. 
Most published studies are limited to single treatment types, and we examined if observed 
associations were restricted in some manner due the characteristics of research subjects 
within specific treatment groups. Treatment specific ORs, similar to those observed in the 
cohort overall, did not show an association between diabetes and high aggressive CaP 
(Table A 1). No association was observed between obesity, independent of diabetes, and 
high aggressive CaP in treatment-stratified models. Race-specific models did not reveal 
differences between Whites or Blacks regardless of treatment type.  
 Research subjects who received both RP and radiation were included in the RP 
group, so we conducted a sensitivity analysis where research subjects that received both 
RP and radiation were excluded from the RP group. Results were similar (data not shown). 
The observed ORs for Gleason sum ≥ 7 (in diabetics vs. non-diabetics) were similar for the 
overall cohort (OR: 0.93; 95% CI: 0.75, 1.16), and race-specific groups [Whites (OR: 0.96, 
95% CI: 0.68, 1.34); Blacks (OR 0.92, 95% CI: 0.69, 1.23)]. Obesity, independent of 
diabetes, was associated with Gleason sum ≥ 7 in both the overall cohort (OR: 1.36; 95% 
CI: 1.06, 1.76) and Whites (OR: 1.51; 95% CI: 1.03, 2.20), but not Blacks (OR: 1.23; 95% 
CI: 0.87. 1.75) 
4.3.3 Prevalence Differences 
 Direct comparisons of effect estimates (ORs) between races were uninterruptable 
due to the differing baseline prevalence of high aggressiveness CaP among unexposed 
Whites and unexposed Blacks in our case-only cohort. To address this, we calculated 
prevalence differences (PD) in a supplementary analysis (Table A 2). Prevalence 
differences showed directions of association that were consistent with the results based on 
ORs. Namely, diabetes was not associated with a higher prevalence of aggressive CaP in 
the cohort as a whole, or in Whites or Blacks after adjusting for age, race, screening history, 
study site, education, and BMI. However, obesity, independent of diabetes, was associated 
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with a 7% (PD: 0.07; 95% CI: 0.01, 0.14) increase in the prevalence of high aggressive CaP 
in Whites and a 4% increased prevalence in the cohort as a whole (PD: 0.04; 95% CI: 0.00, 
0.09).  The prevalence difference in Blacks was close to the null  (PD: 0.01; 95% CI: -0.06, 
0.08), although the estimate is imprecise. 
4.4 Discussion 
 Self-reported diabetes was not associated with a composite measure of CaP 
aggressiveness at diagnosis in this population-based cohort of Whites and Blacks with CaP. 
We did not observe any differences in this association between Whites and Blacks. 
However, we found that obesity, independent of diabetes, was associated with high 
aggressive CaP in Whites using our composite measure of CaP aggressiveness.  
 Several studies have reported a positive association between diabetes and CaP 
aggressiveness at diagnosis.21,23,24,123 However, unlike our study, these studies were 
restricted to clinical patient sets receiving a common treatment, with an outcome of Gleason 
sum alone.21,23,24,123 Moreover, only one of these studies adjusted for obesity in their 
analyses.23 D’Amico et al. reported a positive association between diabetes and Gleason 
sum 8-10 (OR: 1.85, 95% CI: 1.25, 2.74) among radiation patients.24 Kang et al reported that 
both type 1 diabetes (OR: 2.05, 95% CI: 1.28, 3.27) and type 2 diabetes (OR: 1.58, 95% CI: 
1.26, 1.99) were associated with Gleason sum 8-10 in another study that used the same 
cohort 123. Jayachandran et al. reported that diabetes was associated with Gleason sum ≥ 7 
(OR: 1.73, 95% CI: 1.22, 2.45) among RP patients from the Shared Equal Access Regional 
Cancer Hospital Database (SEARCH).23  By contrast, we did not find an association 
between diabetes and our composite outcome of CaP aggressiveness, Gleason sum ≥ 7, or 
Gleason sum ≥8 in our population-based cohort as a whole, or in treatment-stratified 
analyses. 
 Our results were consistent with the Cancer of the Prostate Strategic Urologic 
Research Endeavor (CaPSURE) study. Chan et al. reported that a history of diabetes was 
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not associated with higher Gleason score in multivariate analysis.28 Although Chan et al. is 
not population-based, it is similar to our study in its inclusion of men treated with either 
radiation or RP and use of a self-reported measure of diabetes. However, unlike our study, 
Chan et al. modeled diabetes at baseline as the outcome of interest with Gleason score as a 
covariate in a multivariable model, and this could potentially explain the lack of association 
observed.28 The model was designed to predict diabetes status and not Gleason score, and 
it is possible that in the presence of other covariates that are strong risk factors for diabetes, 
including BMI, age, and race, Gleason score no longer remains a significant predictor.  
 Only two studies examined racial differences in the diabetes-CaP aggressiveness 
association among men diagnosed with CaP.21,23 Mitin et al. reported that diabetes was 
associated with a Gleason sum 8-10 in Blacks (OR: 1.84, 95% CI: 1.08, 3.13) and 
nonblacks (OR: 1.59, 95% CI: 1.33, 1.89) treated with radiation.21 By contrast, 
Jayachandran et al. reported that diabetes was associated with high-grade disease 
(Gleason sum ≥ 7) in Whites (OR: 2.28, 95% CI: 1.33, 3.91), but not Blacks (OR: 1.45, 95% 
CI: 0.90, 2.23) treated with RP. 23 Our results did not show a positive association between 
diabetes and our composite measure of high aggressive CaP in either Whites or Blacks. 
Sensitivity analyses with Gleason sum ≥7 as our outcome were consistent with our CaP 
aggressiveness composite outcome, and we did not observe an association between 
diabetes and Gleason sum ≥7 in the overall cohort or either race-group. Results stratified by 
treatment type were consistent with our CaP aggressiveness composite outcome, and no 
significant association was observed between diabetes and Gleason sum ≥ 7 (data not 
shown). Some studies only reported association between diabetes and a higher Gleason 
sum cut-point (i.e. Gleason sum ≥ 8). Therefore we examined the association using this 
higher cut-point 21,24. The higher cut-point did not impact our results, and no significant 
associations were observed in either race-group or in results stratified by treatment type 
(data not shown).  
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 Among the two studies that looked at race differences, Mitin et al. included men 
treated with radiation between 1991 and 2010 and Jayachandran et al. included men treated 
with RP between 1988 and 2008. Our study, by contrast, included men diagnosed with CaP 
between 2004 and 2009. The FDA did not approve use of PSA as a screening test in 
asymptomatic men until 1994.44 Thus Mitin et al. and Jayachandran et al. included men from 
the pre-PSA and PSA screening eras, while our cohort came from the PSA-screening era. 
Cohorts that include men from the pre-PSA screening era, who are likely to have more 
aggressive CaP at diagnosis, may be more likely to show a positive relationship between 
diabetes and CaP aggressiveness at diagnosis. As anticipated we observed a consistent, 
strong inverse association between a positive history of PSA or DRE screening prior to CaP 
diagnosis and high aggressiveness CaP at diagnosis in the overall cohort, Whites, and 
Blacks. Neither of the other two studies that examined race differences adjusted for 
screening history.21,23   
 Given the close relationship between diabetes and obesity, we investigated the role 
of obesity, independent of diabetes, on CaP aggressiveness. This analysis builds on a 
previous PCaP study that found obesity, not adjusted for diabetes, was associated with high 
aggressive CaP in Whites [Obese (OR: 2.00; 95% CI: 1.13, 3.54), Severely obese (OR: 
2.09; 95% CI: 1.06, 4.14)] but not Blacks [Obese (OR: 1.38; 95% CI: 0.85, 2.23), Severely 
obese (OR: 1.71; 95% CI: 1.00, 2.90)].105 Our results, which were consistent with previous 
PCaP reports, showed that obesity, independent of diabetes, was positively associated with 
our composite measure of high aggressive CaP in Whites, but not in Blacks. Obesity, 
independent of diabetes, was associated with Gleason sum ≥ 7 both in the whole cohort and 
Whites. The cohort-level association is likely driven by Whites, since no association was 
observed with obesity, independent of diabetes, and Gleason sum ≥ 7 in Blacks. 
 Two other studies have examined racial differences in the obesity-CaP 
aggressiveness association, and our results are consistent with those observed in an earlier 
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study utilizing the SEARCH database.120 This study reported that moderate and severe 
obesity were significantly associated with pathologic Gleason sum ≥7 in Whites (OR: 2.35; 
95% CI: 1.12, 4.91), but not Blacks (OR: 1.48; 95% CI: 0.71, 3.12).120 Spangler et al., by 
contrast, reported that obesity was not associated with Gleason sum in Whites or Blacks.124 
This inconsistency may result from Spangler et al. having a patient cohort from a single, 
academic health system that may not be representative of the larger CaP population.124 
 Our results suggest the impact of obesity on CaP aggressiveness may vary across 
race, so we examined prevalence differences to further elucidate the role of race. ORs 
across races cannot be compared directly in our case-only cohort, because the prevalence 
of high aggressive CaP in the unexposed (i.e. those with a normal BMI) is not comparable. 
Blacks with a normal BMI were more likely to have high aggressive CaP (22%) than Whites 
with a normal BMI (12%) in our cohort. The prevalence of high aggressive CaP in obese 
Whites is 20%. This prevalence is lower than the prevalence of high aggressive CaP in 
Blacks with a normal BMI. Our findings suggest that obesity may increase the prevalence of 
high aggressive CaP only when the baseline prevalence of high aggressive CaP is relatively 
low, and this may explain why obesity did not increase the prevalence of high aggressive 
CaP in Blacks. Prevalence differences were consistent with the direction of association for 
ORs. We found that obesity, independent of diabetes, was associated with a 7% increase in 
the prevalence of high aggressive CaP in Whites and no significant difference was observed 
in Blacks.  
 A key strength of our study is that it is a population-based study of both Whites and 
Blacks diagnosed with CaP. PCaP is a large, well-characterized, cohort from the PSA 
screening era with detailed epidemiologic, interview, and clinical data, which allow for 
analytic adjustment for factors such as CaP screening history. To our knowledge, previous 
studies that examined racial differences in the association of diabetes and CaP 
aggressiveness at diagnosis were not population-based, encompassed both the pre-PSA 
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and PSA screening eras, did not adjust for CaP screening history, and were limited to 
patients receiving a single treatment modality. Thus our results may provide a more valid 
assessment of diabetes and CaP aggressiveness at diagnosis, and can be generalized to 
the broader population of both Blacks and Whites with CaP and diabetes, particularly in the 
southeastern U.S. In addition, our study included all treatments types received by the CaP 
population.      
 Our study used self-reported diabetes and therefore has some limitations. An 
Atherosclerosis Risk in Communities study (ARIC), reported that the sensitivity of prevalent 
self-reported diabetes ranges from 58.5% to 70.8% and the specificity ranges from 95.6% to 
96.8% depending on the reference definition employed.102 21.6% of all research subjects 
reported having diabetes while 25.5% of research subjects 65 and older reported having 
diabetes in our cohort. This prevalence is similar to estimates by the Centers for Disease 
Control and Prevention (CDC), were 25.9% of individuals 65 and older in the US have 
diabetes.125  However, it is likely that at least some men in our cohort have undiagnosed 
diabetes. The direction of the resulting bias is uncertain. It is possible that men with high 
aggressive CaP at diagnosis are more likely to have undiagnosed diabetes, as these men 
are the least likely to have a regular source of healthcare, resulting in a bias away from the 
null. Another potential limitation of our diabetes measure is that we do not know when 
research subjects were diagnosed and cannot evaluate the duration of diabetes exposure, 
or the severity of disease among diabetics, or how well diabetes was controlled. In addition, 
Black research subjects were more likely than White research subjects to be excluded from 
our analytic sample due to missing exposure, outcome, or covariate information. If excluded 
research subjects were more likely to have aggressive CaP, results in Blacks could be more 
biased than Whites. 
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 The PCaP cohort allowed us the unique opportunity to make population-based 
estimates of the association between diabetes and CaP aggressiveness at diagnosis, and to 
specifically examine this association in a significant number of Black men. 
4.5 Conclusion 
  Our results suggest that diabetes may not be associated with CaP aggressiveness 
at diagnosis in men with CaP. Our results further suggest that association of obesity with 
CaP aggressiveness in men diagnosed with CaP may by limited to Whites. Future studies 
with large numbers of both Whites and Blacks with detailed information on diabetes duration 
and management are needed to further elucidate any racial differences that may exist 
between in CaP aggressiveness.  
  
78 
Table 9. PCaP Research Subject Characteristics 
 All research 
Subjects 




 (n=991)  
Age years  (Mean, SD) 63.0 (7.9) 64.1 (7.9) 61.7 (7.8)  
Screening History (n, %) 
a 
   
    Yes 1838 (89.7) 996 (94.1) 842 (85.0) 
    No 211   (10.3) 62 (5.9) 149 (15.0) 
Study Site    
    North Carolina 973   (47.5) 504 (47.6) 469 (47.3) 
    Louisiana 1076 (52.5) 554 (52.4) 522 (52.7) 
Education (n, %)    
    Less than high school 399   (19.5) 100 (9.5) 299 (30.2) 
    High school graduate or  
    some  college 
1032 (50.4) 497 (47.0) 535 (54.0) 
    College graduate or   
    above 
618   (30.2)  461 (43.6) 157 (15.8) 
BMI (n, %) 
b 
   
   Normal  374 (18.3) 172 (16.3) 202 (20.4) 
   Overweight  881 (43.0) 486 (45.9) 395 (39.9) 
   Obese  794 (38.8) 400 (37.8) 394 (39.8) 
Treatment 
c 
   
   RP 1012 (49.4) 551 (52.1) 461 (46.5) 
   Radiation 395   (19.3) 214 (20.2) 181 (18.3) 
   Neither 642   (31.3) 293 (27.7) 349 (35.2) 
Diabetes (n, %) 
d 
   
   Yes 443   (21.6) 177 (16.7) 266 (26.8) 
   No 1606 (78.4) 881 (83.3) 725 (73.2) 
CaP Aggressiveness 
e 
   
   Low  1045 (51.0)  586 (55.4) 459 (46.3) 
   Intermediate  638   (31.1)  310 (29.3) 328 (33.1) 
   High  366   (17.9)  162 (15.3) 204 (20.6) 
 
 a 
Screening history was based on self-report and defined as having at least one PSA or DRE prior to CaP 
 diagnosis 
 b
 Research subjects were categorized as normal (BMI 18.5 to <25), overweight (BMI 25 to <30), or obese (BMI ≥ 
30) 
  c 
Research subjects that had both RP and radiation were included in the RP group while the radiation 
  group included research subjects who had either external beam radiation or brachytherapy 
 d
 Based on self-report 
 e
 High aggressive CaP was defined as Gleason sum ≥8, or PSA >20 ng/ml, or Gleason sum =7 and  
  clinical stage cT3-cT4. Low aggressive CaP was defined as Gleason sum <7 and clinical stage cT1-cT2 and  






Table 10. Prevalence Odds Ratios (OR) for High Aggressive CaP 
  


























Diabetes          
     No 1606 276 Ref 881 130 Ref 725 146 Ref 
     Yes 
 
443 90 1.04 (0.79,1.37)  177 32 1.00 (0.65, 1.57)  266 58 1.07 (0.75, 1.53)  
BMI           
     Normal 
 
374 64 Ref 172 20 Ref 202 44 Ref 
     Over-    
     weight- 
 
881 140 1.03 (0.74, 1.44)  486 64 1.29 (0.75, 2.24)  395 76 0.93 (0.60, 1.42)  
     Obese 
 
794 162 1.37 (0.99, 1.92)  400 78 1.98 (1.14, 3.43)  394 84 1.09 (0.71, 1.67)  
 a Model included diabetes, age in years, race, screening history, study site, education, and BMI 
b




CHAPTER 5: THE ASSOCIATION OF DIABETES AND OBESITY WITH PROSTATE 
CANCER PROGRESSION IN A WHITE AMERICAN AND BLACK AMERICAN COHORT: 
HCAP-NC 
5.1 Introduction  
 Prostate cancer (CaP) is the most common cancer in men in the United States, and 
14% of men will be diagnosed with CaP during their lifetime.1 There will be an estimated 
180,890 new cases of CaP and 26,120 CaP deaths in the U.S. during 2016.34 CaP is a 
cancer that disproportionally affects Black Americans (Blacks) who are more likely to be 
diagnosed with and die from CaP.1 In addition, 20-30% of men treated with radical 
prostatectomy and 30-50% of men treated with radiation will experience CaP recurrence 
within 10 years.126 
 Previous studies have suggested that both diabetes and obesity may be associated 
with CaP recurrence.23,28,31,32,127 Insulin is a growth factor for CaP cells.128,129 Diabetics, with 
potentially lower circulating levels of insulin, are hypothesized to have a low-growth 
environment, where there is “selection pressure” that allows only more aggressive CaP to 
survive.23 Obesity, a strong risk factor for diabetes, is also potentially associated with both 
CaP aggressiveness at diagnosis and recurrence.116,127 Specifically, obese men are more 
likely to have lower testosterone levels and hyperinsulinemia, both of which have been 
associated with CaP aggressiveness at diagnosis and recurrence 127,130-134. Moreover, CaP 
may be harder to detect in obese men. Obese men can have lower Prostate Specific 
Antigen (PSA) levels, larger prostates, and less accurate Digital Rectal Exams (DRE).127,135 
Factors such as these can all contribute to the diagnosis of CaP at a later, more aggressive 
stage, which potentially increases the risk for subsequent CaP progression (recurrence or 
persistence). 
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 We examined the association of diabetes and obesity with CaP progression in the 
Health Care Access and CaP Treatment in North Carolina (HCaP-NC) cohort, a follow-up 
study of North Carolina men participating in the North Carolina-Louisiana CaP Project 
(PCaP). Previous research on diabetes and obesity has been limited to clinically-based 
sample groups and only one study examined racial differences in the association between 
diabetes and CaP recurrence 23. Moreover, the two studies that examine racial differences 
between obesity and CaP recurrence have reported inconsistent results 120,124. HCaP-NC is 
a population-based cohort of men with incident CaP, followed for on average 5 years after 
diagnosis, over-sampled for Blacks, and included detailed clinical, epidemiologic and 
interview data, making it an ideal cohort to study the association of obesity and diabetes on 
CaP progression in both White Americans (Whites) and Blacks. 
5.2 Methods 
5.2.1 Study Population and Data Collection 
 PCaP has been described in detail previously 136. Briefly, PCaP is a population-
based cohort of men from North Carolina and Louisiana diagnosed with histologically 
confirmed first diagnosis of adenocarcinoma of the prostate between July 2004 and October 
2007 by state tumor registries. Eligible men were 40-79 years old at CaP diagnosis, able to 
complete the study interview in English, did not live in an institution (i.e. nursing home), and 
were not cognitively impaired at the time of the interview. Moreover, eligible men had to self-
identify as African American/Black or Caucasian/White in response to the open-ended 
question, “What is your race?” 
 Research participants were visited, in-home, by a Registered Nurse. The nurse 
administered a questionnaire, took biologic samples, and made anthropometric measures. 
The study questionnaire included questions on comorbidities such as diabetes, education 
level, and CaP screening history. Medical records abstraction included information regarding 
physical examinations and laboratory assays at or near diagnosis, clinical stage, Gleason 
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grade, PSA measures, and initial CaP treatment. Informed consent for the interview and 
specimen collection as well as release of tumor tissue and medical records was obtained 
during the in-home visit.   
 North Carolina PCaP participants were invited to participate in HCaP-NC, the follow-
up study, in 2009. The follow-up cohort has been described previously 137. Briefly, 822 
research participants were enrolled in HCaP-NC, 366 Black and 456 White. Research 
participants completed questionnaires and provided permission for medical records release 
annually for 3 years. On average, research participants were 5 years post diagnosis at the 
completion of follow-up. Follow-up medical records (n=822) were received for 80% of 
baseline PCaP research subjects from North Carolina (n=1031). Follow-up medical record 
abstraction included post-treatment PSA values, and any secondary treatment received.   
5.2.2 Analytic Sample 
 HCaP-NC included follow-up medical records for 822 research participants. Men 
were excluded if the CaP progression status could not be determined. The exclusions 
included: men who received no treatment or only watchful waiting (n=59), received ADT as 
the primary treatment (n=31), were men treated with radical prostatectomy with no PSA 
measure within 6 months of surgery (n=33), or had missing information essential to 
determine progression status including missing treatment date, missing PSA values, (n=24), 
or other clinical factors that hampered determination (n=3). ADT was considered the primary 
treatment type if the research participant received only ADT or ADT was given more than 
one year prior to radiation initiation (if ADT was received prior to radical prostatectomy, 
radical prostatectomy was considered the primary treatment type). Clinical factors for 
exclusion included CaP progression at time of diagnosis and included 2 men with PSAs 
>100 at diagnosis, and a man that received chemotherapy as initial CaP treatment. 
Ultimately, CaP progression was determined for 672 research participants. An additional 20 
men were excluded for missing exposure or covariate information, and 5 for underweight 
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BMI. The final analytic cohort consisted of 647 research participants. 
5.2.3 Outcome, Exposure, and Covariates 
 The primary outcome evaluated in this study is CaP progression, which we defined 
by PSA levels and treatment patterns in the follow-up period.  Progression was defined as 
either prostate cancer persistence after unsuccessful first course of treatment or recurrence 
among men for whom initial treatment was successful. For each man, following up began on 
date of treatment start and follow-up ended at either date of progression for men with 
progression or date of last PSA measure available for men that were censored. 
 Research participants treated initially with radical prostatectomy were categorized as 
having a CaP progression event if the man had biochemical recurrence (BCR), persistent 
disease, or treatment failure. BCR was determined using the definition recommend by the 
American Urological Association (AUA) and was defined as a PSA ≥ 0.2 ng/ mL, confirmed 
with a 2nd PSA of ≥ 0.2 ng/ mL after achieving nadir.66 Nadir was defined as an undetectable 
PSA (PSA <0.1).  Men with BCR were recorded as having CaP progression at first PSA ≥ 
0.2 ng/mL after nadir, given that there was a second confirmatory PSA.66 Persistence was 
defined as not achieving nadir within 6 months after surgery. Men with persistence were 
recorded as having CaP progression at 90 days after surgery. We chose 90 days because 
men that are successfully treated with radical prostatectomy typically achieve nadir within 90 
days. No man with BCR had a time-to-event of less than 90 days. Treatment failure was 
defined as post radical prostatectomy treatment for CaP (secondary treatment) after 
achieving nadir and included radiation, androgen deprivation therapy, or chemotherapy. 
Research participants were recorded as having a progression event at the date the 
secondary treatment was initiated. All other men were considered successfully treated and 
were censored at end of follow-up (i.e. date of last PSA measurement available). Adjuvant 
radiation and adjuvant ADT were not considered secondary treatment. Radiation or ADT 
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that was initiated ≤ 6 months after radical prostatectomy was considered adjuvant. All other 
men were considered successfully treated.  
  Research participants treated initially with radiation (either external beam radiation 
or brachytherapy) were categorized as having a CaP progression event if the man had BCR 
or treatment failure. Men treated with radiation do not typically achieve a post-treatment 
nadir PSA that is undetectable138, and as such persistence cannot be defined in this group. 
BCR was determined using the Phoenix definition and was defined as Nadir + 2 ng/ mL.67  
Nadir was defined as the lowest PSA achieved after initiation of radiation. Men with BCR 
were recorded as having a CaP progression at the first PSA that was 2 ng/mL above nadir 
(Phoenix definition).67 Treatment failure was defined as post-radiation treatment for CaP 
(secondary treatment) and included radiation, ADT, or chemotherapy. Research participants 
were recorded as having a CaP progression event on the date the secondary treatment was 
initiated.  All other research subjects were considered successfully treated and were 
censored at the end of follow-up (i.e. date of last PSA measurement available). Adjuvant 
ADT, defined as ADT initiated ≤ 1 year after start of radiation, was not considered a 
secondary treatment.  
  Examples of men with the more common CaP progression outcomes and successful 
treatment can be seen in appendix figures B 1-B 9. 
   Our primary exposures of interest are diabetes and obesity. At baseline, men self-
reported diabetes status during the in-home interview when asked the question, “Has a 
doctor or other health professional ever told you that you had diabetes or sugar diabetes?” 
Responses were recoded as “yes”, “no”, “refused”, or “don’t know”. Obesity was determined 
using body mass index (BMI) and calculated based on anthropometric measurements made 
by the study nurse at the time of the baseline PCaP in-home visit. Men were categorized as 
obese if BMI was ≥ 30 using the World Health Organization cut-point.139 We analyzed 
obesity as dichotomous variable to maximize power. 
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 Covariates were selected based on known confounders in the literature and to 
maintain consistency with prior PCaP studies and included self-reported race, age at 
diagnosis, and education. We also describe the prevalence of screening history and CaP 
aggressiveness in our cohort, but they were not included in our final model. Race was based 
on self-report, and all research participants were categorized as either White or Black. Age 
was calculated based on age at diagnosis and coded as a continuous variable. Education 
was also based on self-report at baseline and men were categorized as having a college 
degree or not. Screening history was based on self-report and defined having at least one 
PSA or DRE prior to CaP diagnosis. High CaP aggressiveness was defined both using 
Gleason sum alone (Gleason sum ≥ 8) and a composite measure of CaP aggressiveness 
that has been previously developed for PCaP.101 High aggressive tumors were defined as 
Gleason sum ≥8, or PSA >20 ng/ml, or Gleason sum =8 and clinical stage cT3-cT4 in the 
composite measure.101  
5.2.4 Statistical Analysis 
 Progression-free survival was compared in both diabetic and non-diabetic men and 
obese and non-obese men using Kaplan-Meier plots. Kaplan Meier plots were truncated at 6 
years of follow-up (average follow-up was 5 years), because only 5 patients had more than 
six years of data. However, all men including those with greater than 6 years of follow-up 
(n=5) were retained in all analytical models.  
 The Cox Proportional Hazards model was used to assess the association of diabetes 
and obesity independent of diabetes with CaP progression in our primary analysis. 
Multivariable models were adjusted for race, age, and education. (We did not include CaP 
screening history in our model as greater than 94% of our cohort was screened). The 
proportional hazard assumption for each categorical covariate was assessed by examining 
the log(-log (Survival Probability)) plots. If the plots indicated a potential violation of the 
proportional hazards assumption, we examined whether the interaction between time and 
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the relevant covariate was statistically significant (p-value ≤ 0.05). For continuous variables, 
the proportional hazard assumption was assessed using Schoenfeld Residuals. To examine 
racial differences, models were stratified by race.  
 In a secondary model, we examined obesity without adjustment for diabetes using 
the approach described previously.  
 All analyses were conducted using SAS 9.4 (Cary, NC). 
5.3 Results 
5.3.1 Characteristics of HCaP-NC Cohort 
 The analytic cohort consisted of 647 research participants of whom 363 were Whites 
and 284 were Blacks. The prevalence of diabetes (17.9% analytic cohort vs. 20.2% HCaP-
NC), obesity (38.2% vs. 37.8%), college education (41.3% vs. 37.8%), Gleason sum ≥8 
(8.9% vs. 10.2%), and our composite measure of high aggressive CaP (12.8% vs. 15.0%) 
were similar in our analytic cohort as compared to the overall HCaP-NC cohort. However, 
excluded Black men were less likely to have a college education (8.6% included men vs. 
23.6% excluded men) and more likely to have high aggressive CaP (34.2% vs. 14.4%) than 
Black men included in the analytic cohort. Excluded White men were more likely to diabetic 
(28.6% vs. 13.0%) and less likely to have a college education (38.7% vs. 55.1%) than White 
men included in the analytic cohort. 
 The CaP progression status of research participants can be seen in Table 11. In 
total, 20.9% of the cohort had a CaP progression. Across men treated initially with either 
radical prostatectomy or radiation, BCR occurred in 11.0% of men (n=71) and treatment 
failure occurred in 4.1% (n=26) of men. 5.9% (n=38) of men treated initially with radical 
prostatectomy had persistent progression. Blacks were more likely to have CaP progression 
(25.0%) as compared to Whites (17.6%).  
 Research participant characteristics by race and progression status can be seen in 
Table 12. Men who were successfully treated versus those who had CaP progression were 
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equally likely to have diabetes as those who had CaP progression (18.0% vs 17.8%, 
respectively). Blacks were more likely to be diabetic than Whites. Obesity was more frequent 
in research participants with CaP progression than those that were successfully treated. 
This difference was more pronounced in Whites (45.3% of Whites with CaP progression 
were obese compared to 30.1% of those with successful treatment) than Blacks (46.5% of 
Blacks with progression were obese compared to 44.6% of those with successful treatment). 
Whites were more likely to be college educated than Blacks regardless of whether they had 
CaP progression or treatment success. Greater than 94% of the cohort was screened 
regardless of whether the man had CaP progression. High aggressive CaP at diagnosis was 
more prevalent in men who experienced CaP progression (26.7%) than those with treatment 
success (9.2%). The prevalence of high aggressive CaP at diagnosis was similar in White 
men (28.1%) and Black men (25.4%) with CaP progression. The age at diagnosis was 
similar for those with CaP progression or treatment success.  
5.3.2 Time to Progression 
  The mean progression-free survival time was 5.0 years calculated based on the 
Kaplan-Meier estimator of the progression-free survival probability. Kaplan-Meier plots for 
diabetes and obesity are presented in Figures 6 and 7, respectively. Kaplan-Meier survival 
estimates indicated no differences in progression-free survival for diabetics vs. non-diabetics 
(log rank test p-value =0.92). However, Kaplan-Meier estimates for obesity indicated that 
non-obese men had a better survival probability than obese men (log rank test p-value = 
0.03). No violation of the proportional hazard assumption was found for our primary 
exposures or our model covariates. 
 Table 13 shows hazard ratios (HRs) and 95% confidence intervals for CaP 
progression in the analytic cohort. Race-stratified models are also presented. Diabetes was 
not associated with CaP progression in the overall cohort (HR: 0.86, 95%CI: 0.54, 1.35) 
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after adjustment for obesity, age at diagnosis, race, and college education. Race-stratified 
models similarly showed no association between diabetes and CaP progression in Whites 
(HR: 1.03, 95% CI: 0.50, 2.13) and a weakly decreased HR among Blacks (HR: 0.77, 95% 
CI: 0.43, 1.39). However, obesity independent of diabetes was positively associated with 
CaP progression in Whites  (HR: 1.79, 95% CI: 1.08, 2.97), but not the cohort as a whole 
(HR: 1.40, 95%CI: 0.99, 1.99) or Blacks (HR: 1.15, 95% CI: 0.71, 1.86). 
 Because obesity independent of diabetes was significantly associated with CaP 
progression in Whites, in a secondary model we examined the impact of obesity without 
adjustment for diabetes. Results were consistent with our primary analysis. Obesity was 
associated with CaP progression in Whites (HR: 1.80, 95% CI: 1.09, 2.96), but not Blacks 
(HR: 1.10, 95% CI: 0.69, 1.76) or the overall cohort (HR: 1.37, 95% CI: 0.97, 1.93) in 
multivariable models.  
5.4 Discussion   
 Self-reported diabetes was not associated with CaP progression among Whites or 
Blacks in this population-based cohort with incident CaP. Obesity was associated CaP 
progression in Whites only, unadjusted and adjusted for diabetic status. 
 Consistent with our study, most previous clinic-based studies have observed no 
overall association between diabetes and BCR.23,28,30,95-97 However, there are some 
exceptions. Chan et al. observed a positive association between diabetes and BCR  in the 
Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE) only among the 
sub-group of patients that were in a low-risk D’Amico prognostic group.28 In addition, Patel et 
al. also observed a positive association between diabetes and BCR (HR: 1.55, 95%CI: 1.03, 
2.33) among patients treated with radical prostatectomy in the Columbia University 
Oncology Database.31 This study matched men with diabetes with non-diabetic controls 
using their 5-year risk of recurrence according to the preoperative Kattan nomogram.31 Both 
the D’Amico risk-group classification and the Kattan nomogram are designed to predict risk 
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of CaP recurrence, and could be thought of as proxies for the outcome, CaP 
progression.60,61,140 Matching or stratification by these measures could partially explain why 
results from Chan et al. and Patel et al. are inconsistent with other findings.28,31 It is possible 
that matching on the clinical risk of recurrence using the Kattan nomogram, such as that 
done by Patel et al, resulted in otherwise weak predictors of BCR (i.e. diabetes) having a 
positive association with BCR. One potential reason that Chan et al. may have observed an 
association only in the low-prognostic D’Amico risk group could be that low-risk men have a 
greater susceptibility to the effects of diabetes while men in the high D’Amico risk groups 
have a uniformly greater risk or recurrence regardless of exposure status.28 
 Research examining racial differences in the association between diabetes-CaP 
progression is limited. Only one previous study of radical prostatectomy patients (n=1262), 
has examined racial differences in the association of diabetes with BCR.23 Jayachandran et 
al., reported diabetes was significantly associated with BCR only in white, obese men from 
the Shared Equal-Access Regional Cancer Hospital (SEARCH) database, consisting of men 
from Veterans Affairs Hospitals. No association was observed in black men regardless of 
obesity status.23 The authors suggest that race and obesity may modify the association 
between diabetes and BCR.23 However, when we restricted our analysis to obese men, we 
observed no association between diabetes and progression in obese men overall (HR: 0.74, 
95%CI: 0.40, 1.34), White obese men (HRl 0,83, 95%CI; 0.32, 2.19), or Black obese men 
(HR: 0.67, 95% CI: 0.31, 1.45). 
 In contrast to diabetes, most prior studies have reported a positive association 
between obesity and BCR.120-122,124,141,142 A 2011 meta-analysis reported that a 5kg/m2 
increase in BMI was significantly associated with BCR (RR: 1.21, 95% CI: 1,11, 1.31).127 In 
our overall cohort, that had a similar number of Black and White men, we observed an 
elevated HR for CaP progression in obese men. The positive association between obesity 
and progression was statistically significant only in White men, both with and without 
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adjustment for diabetes. Two previous studies have examined racial differences in the 
obesity-BCR association. Jayachandran et al. reported that obesity was associated with 
BCR in both Blacks and Whites using the SEARCH database.120 By contrast, a study at the 
University of Pennsylvania oncology clinics, Spangler et al. reported that obesity was 
significantly associated with BCR in Blacks but not European Americans  although the HR 
was elevated.124 Our identification of a statistically significant positive association in Whites 
is consistent with that observed in the SEARCH database. Unlike our study, both 
Jayachandran et al. and Spangler et al. were limited to patients that were treated with 
radical prostatectomy and had clinically-derived study populations.120,124 Our study adds to 
the current evidence as we had a population-based, racially-diverse cohort of men that 
received either radical prostatectomy or radiation.  
 Another important factor to consider is model adjustment. Both Jayachandran et al. 
and Spangler et al adjusted for prostate tumor characteristics in their analytic models.120,124 
We chose not to adjust for prostate tumor characteristics in our primary models because 
tumor characteristics are a mediator between our primary exposures, diabetes and obesity, 
and CaP progression (i.e. obesity contributes to tumor aggressiveness at diagnosis which in 
turn promotes CaP progression). It is usually advisable that mediators not be part of the 
adjustment set.143 However, to be comparable with prior literature in sensitivity analyses we 
adjusted for both Gleason sum ≥8 alone and our composite measure of high aggressive 
CaP.101 Additional adjustment for Gleason sum ≥8 in our multivariable model did not impact 
results, and obesity remained positively associated with CaP progression in Whites both 
when we controlled for diabetes (HR: 1.69, 95%CI: 1.01, 2.81) and when we did not (HR: 
1.70, 95%CI: 1.04, 2.82). No significant association was observed in Blacks or the cohort as 
a whole. When we adjusted for the composite measure of high aggressive CaP among 
Whites, the HR for obesity was of a similar magnitude to our primary model both when we 
did (HR: 1.62, 95% CI: 0.98, 2.69) and did not control for diabetes (HR: 1.33, 95%CI: 0.95, 
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1.86). No significant association was observed in Blacks or the cohort as a whole. 
Consistent with prior analyses, diabetes was not associated with CaP progression in the 
cohort as whole or in either race-group when we additionally adjusted for Gleason sum ≥8 or 
the composite measure of high aggressive CaP. 
 We also explored alternate BMI cut-points for obesity. Recent research has 
suggested that Blacks may be at risk for diabetes at lower BMIs than their White 
counterparts.144 Because we did not observe an association between obesity and 
progression in Blacks, we examined obesity using a lower cut-point. Based on Chiu et al., 
we defined obesity in Blacks as a BMI of ≥26144. Our results were consistent with our prior 
analyses and no association was observed between obesity and CaP progression both 
when we did (HR: 1.24, 95% CI: 0.69, 2.21) and did not adjust for diabetes (HR: 1.18, 95% 
CI: 0.67, 2.09). 
 Our study was limited by the use of self-reported diabetes. The sensitivity of 
prevalent self-reported diabetes can range from 58.5% to 70.8% and the specificity can 
range from 95.6% to 96.8% depending on the reference definition employed.102  However, 
our estimates of diabetes prevalence are consistent with recent estimates from the 
Behavioral Risk Factor Surveillance System (BRFSS).145 According to BRFSS among 
individuals aged 65-74 in North Carolina the diabetes prevalence is 20.1% and 29.6% in 
Whites and Blacks respectively.145 This is consistent with the diabetes prevalence in our 
cohort among both White men (18.3%) and Black men (31.3%) aged 65-74. However, it is 
likely that at least some men in our cohort have undiagnosed diabetes. The direction of the 
resulting bias is uncertain. It is possible that men with high aggressive CaP at diagnosis are 
more likely to have undiagnosed diabetes, as these men are the least likely to have a 
regular source of healthcare, resulting in a bias away from the null. Moreover, we do not 
know the duration of diabetes exposure, the severity of diabetes, or how well diabetes was 
controlled. However, when Jayachandran et al. adjusted for diabetes duration (<5 years or ≥ 
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5 years), the association with BCR did not significantly change.23  In the two studies that 
examined the association between HbA1C levels, a measure of diabetes severity, and 
recurrence results were inconsistent. 29,32 It is possible variations in diabetes management 
could have impacted our results.  
 A major strength of our analysis is that it is based on a large, well-characterized, 
population-based study of both White and Black men with incident CaP, followed for on 
average 5 years after diagnosis. This is the first study to define CaP progression in the 
HCaP-NC cohort, and to describe specific progression subtypes including persistence, BCR, 
and treatment failure. As such this population-based study adds to the limited and 
inconsistent clinic-based studies of obesity, diabetes and CaP progression among Blacks, 
and may be generalized to a broader population. 
5.5 Conclusion 
 Our study found that diabetes was not associated with CaP progression in the cohort 
as a whole, Whites, or Blacks. Obesity independent of diabetes was associated with CaP 
progression in Whites, but not Blacks. Similarly, when we did not control for diabetes, 















                                                
n (% of All 
Research 
Participants) 
n  (% of All 
Whites) 
n (% of All 
Blacks) 
Radical Prostatectomy (n=469)    
     Progression     
        Biochemical  
        Recurrence 
a 
48 (7.4) 25 (6.9) 23 (8.1) 
        Persistence 
b 
38 (5.9) 19 (5.2) 19 (6.7) 
        Treatment Failure 
c 
25 (3.9) 9 (2.5) 16 (5.6) 
     No Progression 358 (55.3) 229 (63.1) 129 (45.4) 
    
Radiation (n=178)    
       
Progression    
        Biochemical     
        Recurrence 
d
 23 (3.6) 10 (2.8) 13 (4.6) 
        Treatment Failure 
e
 1 (0.2) 1 (0.3) 0 (0.0) 
     No Progression 154 (23.8) 70 (19.2) 84 (29.8) 
 
   
  TOTAL PROGRESSION 135 (20.9) 64 (17.6) 71 (25.0) 
  TOTAL NO PROGRESSION 512 (79.1) 299 (82.4) 213 (75.0) 
a 
Biochemical recurrence was defined using the American Urological Association (AUA) definition: a 
PSA ≥ 0.2 ng/ mL confirmed with a 2nd PSA of ≥ 0.2 ng/ mL after achieving nadir. Nadir was defined 
as an undetectable PSA (PSA <0.1). 
b 
Research subject does not achieve nadir after radical prostatectomy. Nadir is defined as an 
undetectable PSA (PSA <0.1). 
c 
CaP progression is defined by primary treatment failure. Subject received post radical prostatectomy 
treatment for CaP (secondary treatment). 
d 
BCR was characterized using the Phoenix definition: Nadir + 2 ng/ mL. Nadir was defined as the 
lowest PSA achieved after initiation of radiation 
e 
CaP Progression is defined by primary treatment failure. Subject received post radiation treatment    
for CaP (secondary treatment). 
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Table 12. Characteristics of HCaP-NC Research Participants 




































      
    No 420 (82.0) 111 (82.2) 261 (87.3) 55 (85.9) 159 (74.7) 56 (78.9) 
    Yes 92 (18.0) 24 (17.8) 38 (12.7) 9 (14.1) 54 (25.4) 15 (21.1) 
Obese       
    No 327 (63.9) 73 (54.1) 209 (69.9) 35 (54.7) 118 (55.4) 38 (53.5) 
    Yes 185 (36.1) 62 (45.9) 90 (30.1) 29 (45.3) 95 (44.6) 33 (46.5) 
College 
Educated 
      
    No 290 (55.6) 90 (66.7) 129 (43.1) 34 (53.1) 161 (75.6) 56 (78.9) 
    Yes 220 (43.4) 45 (33.3) 170 (56.9) 30 (46.9) 52 (24.4) 15 (21.1) 
Race       
    White 299 (58.4) 64 (47.4) ---- ---- ---- ---- 




      
    No 29 (5.7) 7 (5.2) 10 (3.3) 3 (4.7) 19 (8.9) 4 (5.6) 






      
    No 465 (90.8) 99 (73.3) 275 (92.0) 46 (71.9) 190 (89.2) 53 (74.7) 
    Yes
 a 
47 (9.2) 36 (26.7) 24 (8.0) 18 (28.1) 23 (10.8) 18 (25.4) 
Gleason Sum 
≥ 8 
      
     No 479 (93.6) 112 (83.0) 279 (93.3) 53 (82.8) 200 (93.9) 59 (83.1) 

















Screening history was based on self-report and defined having at least one PSA or DRE prior to 
CaP diagnosis 
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Model included diabetes, obesity, age at diagnosis, race, and college education 
b
 Model included diabetes, age at diagnosis, race, and college education  
c
 Model included diabetes, obesity, age at diagnosis, and college education 
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CHAPTER 6: CONCLUSIONS 
6.1 Summary of Findings 
 The purpose of this dissertation was to utilize the North Carolina-Louisiana PCaP 
cohort, a large, well-characterized, population-based study of both White and Black 
research participants with incident CaP to investigate the association between diabetes and 
CaP aggressiveness. Additionally, we utilized the HCaP-NC cohort, the North Carolina 
PCaP sub-group followed for an average of 5 years after diagnosis, to explore the 
association between diabetes and CaP progression, defined as either persistence or 
recurrence of prostate cancer following definitive treatment. Moreover, because PCaP over-
sampled black research participants we were able to investigate the role of race in both the 
diabetes-CaP aggressiveness and diabetes-CaP progression associations.  
 This study found that diabetes was not associated with high aggressive CaP at 
diagnosis in the cohort as a whole, Whites or Blacks. Similarly, in our follow-up cohort, we 
found that diabetes was not associated with CaP progression in the cohort as a whole, 
Whites, or Blacks. Although examining obesity was not part of our primary aims, there is a 
close relationship between obesity and diabetes, and obesity is one of the strongest known 
risk factors for diabetes.116 As a result, our manuscripts (Chapter 4 and Chapter 5) also 
highlighted the association of obesity with CaP aggressiveness and progression. We found 
that obesity, independent of diabetes, was positively associated with high aggressive CaP in 
Whites, but not Blacks (Chapter 4). In Chapter 5, we similarly found that obesity, 




6.2 Strengths and Limitations 
 This was the first study to examine the association of diabetes with CaP 
aggressiveness and CaP progression using a racially diverse, population-based cohort of 
both Whites and Blacks. Previous studies that examined the diabetes-CaP aggressiveness 
and the diabetes-CaP progression associations were limited to clinic-based samples or 
single-treatment types. Our study included all treatment types typically seen in prostate 
cancer populations including radical prostatectomy and radiation. Aim 1 also included 
research subjects treated primarily with ADT or those that did not receive treatment. This is 
also the first study to classify the progression status of men from HCaP-NC, and specifically 
to classify men who progressed as recurrent or persistent. 
 The use of the PCaP population offered us several key advantages. Because PCaP 
enrolled Blacks and Whites at an equal rate using a randomized recruitment method, we 
had a large cohort of Black men, allowing us to examine race-specific associations. 
Moreover, detailed interview data allowed us to adjust for factors such as PSA and DRE 
screening history unlike other clinic-based studies. This is important given the strong inverse 
association between screening and CaP aggressiveness at diagnosis. Another unique 
feature of this study is that it is a population-based study with detailed clinical data, an 
average of 5-years of follow-up after diagnosis, including secondary treatment and post-
treatment PSA monitoring values. This allowed us to determine progression in a population-
based setting. As such our results our more generalizable and may improve validity over 
previous studies that did not include all treatments typically seen in prostate cancer patients, 
encompassed both the pre-PSA and PSA screening eras, and did not adjust for screening 
history.  
 Despite these strengths, our study did have some limitations. Our measure of 
diabetes is self-reported and thus likely failed to identify all men with diabetes. The direction 
of the resulting bias is uncertain. Men with undiagnosed diabetes are likely to be those with 
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limited access or interaction with the healthcare system. As such these men may be more 
likely to have a delayed CaP diagnosis, resulting in an increased risk for aggressive tumors 
at diagnosis and progression. This could bias our results away from the null. Even among 
men that reported having diabetes, we were not able to account for the severity or duration 
of diabetes. Throughout the disease-course, insulin-levels can fluctuate and treatment can 
change. Insulin promotes prostate cell growth115, and men with higher insulin levels may be 
more likely to have more aggressive CaP and progression. We were unable to account for 
such changes over the disease-course.   
 Additional limitations include missing data for some PCaP participants. This includes 
the lack of detailed clinical follow-up data for Louisiana participants for whom progression 
status could not be determined, limiting our sample size and power. Moreover, in Aim 1 
Black men were more likely to be excluded than White men due to missing exposure, 
outcome, or covariate data. Black men were also more likely to be excluded from HCaP-NC 
follow-up study than White men (Aim 2). These exclusions could have resulted in a selection 
bias. If excluded subjects were more likely to have high aggressive CaP or CaP progression 
then the results in Blacks could be more biased toward the null than the results in Whites. 
6.3 Public Health Impact and Avenues for Further Research   
 Black men are more likely to be diagnosed with and die from prostate cancer.1 
However, in our study we found obesity, independent of diabetes, was associated with CaP 
aggressiveness and progression only in White men. Although our results would suggest that 
perhaps obesity, independent of diabetes, is a risk-factor for adverse outcomes only in 
White men, the potential for these risk-factors to impact Black men cannot be ruled out at 
this time.  
 Black men have a higher baseline prevalence of CaP aggressiveness and 
progression than their White counterparts even if they are non-diabetic or in the normal 
weight range. It is possible that we only observe an increase in the prevalence of CaP 
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aggressiveness and progression with exposure to factors such as diabetes and obesity 
when the baseline prevalence in relatively low. In Black men an effect may not be 
discernible given the high baseline prevalence. However, if this assumption is correct, it 
raises a broader question of why unexposed (i.e. non-diabetic or normal weight) Black men 
have higher baseline prevalence. There could be unknown, underlying genetic differences 
contributing to the increased prevalence of CaP aggressiveness and progression in Black 
men. Alternatively, external factors such as access to care may contribute to the increased 
baseline prevalence observed in Black men. It is probable that if there is an underlying 
biological process by which obesity or diabetes promotes CaP aggressiveness and 
progression in White men there is a similar biological process in Black men, although 
perhaps masked by stronger external factors. VanderWeele and Robinson recently 
suggested that the “effect of race” is rarely itself a causal effect, but usually an indication of 
other factors associated with race, namely socioeconomic disparities.146 This could certainly 
be true in our study. Even though we accounted for SES by adjusting for education, there 
could be residual, unmeasured confounding by socioeconomic factors such as access to 
specialist care, distance to care, time from diagnosis to treatment, and access to follow-up 
care. If we could fully account for socioeconomic disparities throughout the life-course, it is 
possible that we would not observe racial differences in our outcomes. 
 Another factor to consider is that current PSA and BMI cut-points are not race-
specific. A key factor for diagnostic biopsy referral is PSA levels, particularly during the time-
period of our study when PSA screening was the standard of care. However, it has been 
recently suggested that Black men may have advanced CaP at lower PSA levels.147 This 
could potentially lead to a delayed CaP diagnosis and an increased prevalence of high 
aggressive CaP at diagnosis. Moreover, Black men may also be at risk for diabetes at lower 
BMIs than White men.144 If Black men are physiologically “obese”, but not obese according 
to standard cut points, there could be exposure misclassification in our analysis. However, in 
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a sensitivity analysis we used race-specific BMI cut points for Black men, and our results 
were consistent with those obtained using standard cut-points. Nonetheless the racial 
differences we observed could partially be the artifact of less than ideal PSA and BMI cut 
points for racially diverse populations. 
  There are several areas for further research studies. Our study was the first study to 
evaluate diabetes and CaP aggressiveness and progression in a population-based cohort of 
Blacks and Whites. Future studies with large number of both Black men and White men can 
examine a more direct and comprehensive measure of diabetes. Both the duration of 
diabetes and time between diabetes diagnosis and CaP diagnosis could impact observed 
associations, and partially explain inconsistent results. A diagnosis of diabetes well before a 
CaP diagnosis may have a different effect from a diabetes diagnosis close to after a CaP 
diagnosis. In addition, diabetes management can vary greatly across patients and may differ 
significantly between clinic-based and population-based sample groups. Knowledge of a 
patient’s diabetes medication could potentially impact observed associations given that 
metformin and insulin may have been differential effects on prostate cancer risk.75,148. An 
improved characterization of diabetes severity through measures of Hemoglobin A1c levels 
could also potentially improve validity. Two studies have examined hemoglobin A1c levels, 
either at the time of prostate cancer diagnosis or at time of radical prostatectomy, with risk of 
BCR.29,32 However, this narrow time window may not fully capture the impact of diabetes on 
CaP aggressiveness and progression. Therefore, in addition to accounting for time between 
diabetes and prostate cancer diagnosis, diabetes duration and management, future studies 
could examine hemoglobin A1c levels as a time-varying covariate over an extended time 
range. This would better capture the changing glucose and insulin profile of diabetics over 
the disease-course.  
 In addition, because prostate cancer is often a slow progressing disease, analysis of 
cohorts with longer follow-up (e.g. 10 years) would provide valuable information about the 
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association of exposures such as diabetes and long-term prostate cancer outcomes. When 
we examined diabetes as a time-varying covariate in a sensitivity analysis (included an 
interaction term for time and diabetes), in PCaP with an average of 5 years of follow-up, 
there was an elevated hazard of progression at 3, 4, and 5 years with hazard ratios 
increasing at longer follow-up times in a dose-response fashion, although confidence 
intervals were wide. 
 Finally, this was the first study to determine the CaP progression status of research 
subjects from HCaP-NC. Although this document contains graphs of the 9 most common 
progression outcomes in Appendix B, graphs of PSA values over times including treatments 
received are available for all 822 HCaP-NC patients and can be utilized by researchers in 
the future to evaluate the association of a diverse array of factors with CaP progression. 
PCaP has information available on a large range of factors that could be examined in 
association with progression including, but not limited to food frequency, comorbidities, 
medications, and biomarkers. 
 In conclusion, this study found that diabetes was not associated with CaP 
aggressiveness at diagnosis or progression in Whites or Blacks. Obesity, independent of 
diabetes, was moderately associated with CaP aggressiveness and progression only in 
Whites. However, we cannot rule out an association in Blacks at this time. Obesity is 
associated with several adverse health outcomes, and our study suggests that CaP 
outcomes may also be adversely impacted by obesity. Men with prostate caner should be 
advised about the health benefits of maintaining an appropriate weight, and obese men 
should be monitored closely for CaP progression. Future studies with large numbers of both 
Whites and Blacks with detailed information on diabetes duration and management are 
needed to further elucidate any racial differences that may exist in the association of 
diabetes and obesity with CaP aggressiveness and progression. 
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APPENDIX A: AIM 1 SUPPLEMENTAL TABLES REFERENCED IN CHAPTER 4 
Table A 1. Prevalence Odds Ratios (OR) for High Aggressive CaP by Treatment Type 
















OR (95% CI) 
  
OR (95% CI) 
  
OR (95% CI) 
Diabetes      
     No Ref  Ref  Ref 
     Yes 0.96 (0.59, 1.59)  0.96 (0.42, 2.18)  1.00 (0.54, 1.88) 
 
BMI 
     
     Normal  Ref  Ref  Ref 
     Overweight 1.04 (0.60, 1.81)  0.85 (0.38, 1.91)  1.30 (0.61, 2.80) 
     Obese  1.50 (0.87, 2.61) 
 






















OR (95% CI) 
  
OR (95% CI) 
  
OR (95% CI) 
Diabetes      
      No Ref  Ref  Ref 
      Yes 1.24 (0.72, 2.12)  1.12 (0.46, 2.74)  1.29 (0.65, 2.55) 
 
BMI 
     
     Normal  Ref  Ref  Ref 
     Overweight  1.09 (0.51, 2.37)  1.21 (0.34, 4.29)  1.07 (0.40, 2.89) 
     Obese 1.58 (0.74, 3.39)  1.71 (0.48, 6.06)  1.57 (0.60, 4.09) 
a 
Includes all research that received RP. Research subjects that received both RP and  
radiation were included in this group.
 
b 
Includes patients that received either external beam radiation or brachytherapy 
c
 Model included diabetes, BMI, age, race, screening history, study site, education 
d
 Model included diabetes, age, screening history, study site, education 
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Table A 2. Prevalence Differences (PD) for High Aggressive CaP 
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Model Included diabetes, age in years, race, screening history, study site, education, and BMI 
b




APPENDIX B: AIM 2 SUPPLEMENTAL FIGURES REFERENCED IN CHAPTER 4 
A research participant that was treated initially with radical prostatectomy and had treatment 
success. Follow-up begins on date of surgery; research subject is censored at date of last 
PSA measure available. 
 
 
Figure B 1. Progression Outcome Example 1 
A research participant that was treated initially with radical prostatectomy and had treatment 
success. Follow-up begins on date of surgery; research subject is censored at date of last 
PSA measure available 
 
 
Figure B 2. Progression Outcome Example 2 
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A research subject treated initially with radical prostatectomy and had BCR using the 
American Urological Association (AUA) definition. Follow-up begins on date of surgery; CaP 
progression occurs on first PSA ≥ 0.2 after nadir, given there is a second confirmatory PSA 
≥ 0.2.  
 
 
Figure B 3. Progression Outcome Example 3 
A research participant that was treated initially with radical prostatectomy and had treatment 
failure. Radiation (secondary treatment) that was > 6 months after surgery was considered 
treatment failure. Follow-up begins on date of surgery; CaP progression occurs on date of 
radiation start (i.e. date of secondary treatment initiation). 
 
 
Figure B 4. Progression Outcome Example 4 
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A research participant that was treated initially with radical prostatectomy and had treatment 
success. Radiation (secondary treatment) that was ≤ 6 months after surgery was considered 
as adjuvant therapy and not treatment failure. Follow-up begins on date of surgery; research 
subject is censored at date of last PSA measure available 
 
 
Figure B 5. Progression Outcome Example 5 
A research participant that was treated initially with radiation and had treatment success. 




Figure B 6. Progression Outcome Example 6 
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A research participant that was treated initially with radiation and had BCR using the 
Phoenix definition. Nadir is defined as lowest PSA achieved after radiation initiation. Follow-
up begins on date of radiation start; CaP progression occurs on date PSA level reaches 
nadir plus 2. 
 
 
Figure B 7. Progression Outcome Example 7 
A research participant that was treated initially with radiation and had treatment success. 
ADT (secondary treatment) that was ≤ 1 year after radiation was considered as adjuvant 
therapy and not treatment failure. Follow-up begins on date of surgery; research subject is 
censored at date of last PSA measure available. 
 
 
Figure B 8. Progression Outcome Example 8 
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A research participant that was treated initially with radiation and had treatment failure. ADT 
(secondary treatment) that was >1 year after radiation was considered treatment failure. 
Follow-up begins on date of surgery; CaP progression occurs on date of ADT start (i.e. date 
of secondary treatment initiation) 
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